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Multiple sclerosis (MS) is a chronic neurological disorder characterized by inflammation, myelin loss, 
axonal pathology in the central nervous system and progressive neurological dysfunction. It is presumed 
to be an autoimmune disorder and is believed to arise from complex interactions of both environmental 
and genetic factors. For the majority of affected individuals (80-90%), the disease begins as episodic, 
with full recovery after a relapse, and then over a period of time becomes progressive. In around 10-20% 
of patients the illness is progressive from onset, without clinical remissions. The relapsing phase of the 
disease is mediated by focal bursts of inflammation in white matter in the brain and spinal cord, whereas 
axonal and neuronal loss predominate during the progressive phase. Current therapies serve mainly to 
moderate the initial relapsing-remitting phase, but they have much less effect on disease progression 
and long term disability.1
MS is a common disease, affecting over 2 million people worldwide. The population prevalence 
in North America and Northern Europe is ~0.1 %.2 The disease is characterized by a female excess, the 
female-to-male ratio now exceeds 3.2:1.3 Incidence tends to be low in childhood (2 % of patients with 
MS present before age of 10 years and 5 % before age of 16 years), increases after the age of 18, reaching 
a peak between 20 and 35 years and then declines becoming rare at age older than 50.2
 
Are environmental factors involved in MS?
There is substantial evidence for environmental factors to be important in MS susceptibility. The disease 
incidence and prevalence variates according to geography, and is higher with increasing distance from 
the equator.4-6 Migration from a low to high risk region for MS or from a high to low risk region for MS can 
alter the risk to develop MS,7 indicating that endemic exposures occur and are the primary determinant 
of the disease. However, migration studies are typically unable to establish timing of environmental 
exposures owing to small numbers.
Further evidence for environmental factors being involved in susceptibility for MS comes 
from twin studies. In monozygotic twins the concordance rate is ~30 % instead of the 100 % that is 
expected when only genetic factors are important in susceptibility for MS.8 In Canada, the risk of MS 
for a dizygotic twin of a patient with MS is almost twice the risk for a full non-twin sibling, which may 
implicate environmental factor(s), such as shared timing of gestation, birth, or both.8 
Studies of month of birth in several countries in the northern hemisphere showed latitude-
correlated increased MS risks for May births and decreased risks for November births, compared to 
population controls. In addition to population controls a Canadian study used unaffected siblings as 
a second control group. The unaffected sibling controls confirmed and extended the findings as they 
were, like the population control group, significantly more often born in November compared to their 
affected brothers and sisters. Thus month of birth and MS risk are associated which implies interactions 
between genes and environment. The abrupt change in risk by month suggests a threshold effect for 
both increased and decreased risk, which cannot easily be explained. The risk factors responsible for the 
effect of timing of birth must vary seasonally and are probably related to climate.9 They may act during 
gestation or shortly after birth in individuals born in the northern countries. 
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Finally, the female-to-male MS gender ratio has shown to be increasing for at least 50 years 
in studies performed in Europe and North America. Since there is no indication that MS in men has 
decreased, it seems that the sex ratio change is determined by a preferential increase in affected women. 
These changes in sex ratio occur too fast to be accredited to genetic mutations. The factors must be 
environmental, perhaps resulting from gene-environment interactions.3,10,11 In a study of avuncular pairs 
(aunts/uncles and nieces/nephews), this change in sex ratio has also been shown. The overall sex ratio 
for aunts/uncles was significantly lower than for nieces/nephews. Only in the maternal families this 
difference in sex ratio between two generations was shown. In the paternal families the aunt/uncle ratio 
was not different from the niece/nephew ratio.12
Is there a genetic component in MS? 
Although familial aggregation of MS has long been accepted, systematic age-adjusted recurrence 
risks for relatives of persons with MS were first published in 1988.13 Subsequent studies showed that 
first-, second- and third-degree relatives of patients with MS were more likely to have the disease 
than the general population.14,15 The risk for a first-degree relative of a MS proband (2-5%) is ~20 to 
50 times greater than that for the general population (0.1%).14,16 Studies in twins showed a significant 
excess of concordance in monozygotic (~30 % concordance) as compared to dizygotic twins (~5% 
concordance).8,17-20 In a study of individuals with MS who were adopted, a higher risk in the genetically 
related family was found, whereas no higher risk in the adopting family was found.21 Affected husband 
and wife couples do not occur more frequently than expected by chance. However, the risk for their 
offspring is greater than if just one parent is affected.22 For half-siblings the risk is approximately half 
the risk for full siblings, regardless whether they were raised together or apart.23,24 Together, these data 
suggest that living with someone who has MS only increases your MS risk if you are a relative of that 
person and this risk increases with relatedness. 
Mode of inheritance in MS
Although, data confirm that genetic factors are unequivocally relevant in MS, most MS families contain 
no more than two or three affected individuals and no clear mode of inheritance can be inferred from 
segregation analysis. 
If common variants were to be responsible for MS susceptibility, between 20 and 100 common 
variants, each increasing risk by only a modest factor of 1.2-1.5, would be sufficient to account for the 
prevalence and heritability of MS.25,26 If rare variants were to be responsible for MS susceptibility, many 
hundreds if not thousands of rare variants would be required, even if these individually increase risk by 
as much as 10-20 times.26 In fact we can not know for sure where the balance between common and 
rare variants lies in determining susceptibility for MS, but in line with other complex diseases a complex 
interaction of both common variants with low penetrance and rare variants with high penetrance is 
expected.27
Although a single-gene aetiology can not be ruled out for a subset of pedigrees, no example 
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of a Mendelian variant of MS has yet been found. Larger more extended pedigrees, with a more than 
usual concordant disease expression would be expected, when rare but highly penetrant variants 
explain MS susceptibility. 
Parent-of-origin effect in MS
Genetic-epidemiological studies showed that maternal half-siblings, connected through an unaffected 
mother, were at significantly higher risk of developing MS when compared with paternal half-siblings, 
connected through an unaffected father (2.35% versus 1.31%; P =0.048).24 Avuncular pairs are significantly 
more often connected through unaffected mothers than through unaffected fathers.12 
However, when patients with affected parents were studied, the fathers with MS transmitted 
the disease to their offspring significantly more often than the mothers with MS.28 In a large Canadian 
population-based cohort equal transmission of MS was seen from affected fathers and from affected 
mothers.29 Thus, whenever affected parent-child pairs are left out of the model, there is maternal 
transmission of MS and whenever affected parent-child pairs are studied at the nuclear family level, 
paternal transmission catches up or even exceeds maternal transmission. These observations could be 
the result of technical differences between studies.30 
In the avuncular study a significantly increased niece/nephew sex ratio, compared to the 
aunt/uncle sex ratio was only seen in the maternal families. These data suggest that there is also a strong 
maternal influence on the determination of the sex ratio of MS offspring.29
A parent-of-origin effect in MS could be the result of several mechanisms. These may operate 
differently in alternative inheritance models for MS: genetic versus environmental, or both. One 
of the possible genetic mechanisms is a threshold effect due to an increased number of penetrant 
susceptibility genes in a given parental lineage. Another possibility is the involvement of epigenetic 
mechanisms in disease transmission by the affected parent. Epigenesis refers to a mechanism by which 
environmental factors affect gene expression. This can occur through a wide variety of mechanisms, 
including the selective methylation of DNA bases and modification of histones. The underlying DNA 
sequence is not changed. If epigenesis occurs in utero, which may explain the maternal parent of origin 
effect in MS, it can affect the availability of the critical gene product or modify the risk associated with 
a given gene polymorphism. In this way, it can directly contribute to the risk of a disease. Epigenetic 
effects do not have to occur in all cells from one person, they can also operate only in the cells of specific 
tissues.30 In single-gene disorders, imprinting is a mechanism behind the differential parent-of-origin 
effects observed.31 A third genetic possibility for the parent of origin effect in MS is that the multifactorial 
threshold and epigenetic mechanisms of inheritance occur in conjunction. This is especially likely in 
complex disorders as MS.30 
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Susceptibility genes for MS
The HLA region
The first association of MS with genes in the MHC region was identified in 1972.32,33 Until very recently, 
despite many linkage and association studies, only the HLA-class II region of the HLA-DR2 containing 
haplotype on chromosome 6p21, in both primary progressive and relapsing-remitting patients, was 
significantly associated with MS. Three candidate risk genes of this haplotype, HLA-DRB1*1501 (encoding 
HLA-DR2b), HLA-DRB5*0101 (encoding HLA-DR2a) and HLA-DQB1*0602 (encoding HLA-DQ6), are so 
tightly linked that they are almost invariably inherited together.34 Therefore, classic genetic studies failed 
to discriminate between them. Recently, powerful genetic studies have implicated HLA-DRB1*1501 as 
the main susceptibility allele in MS.35,36 The association is strongest in northern Europeans, but is seen in 
virtually all populations with a notable exception being some Mediterranean populations where MS is 
associated with DR3 and DR4.37,38 
Complex interactions within the HLA region
It has become clear that HLA-DRB1*15 is not the sole risk increasing allele in the MHC region.39-41 HLA-
DRB1*17 increases the risk of MS, but to a lesser extent than HLA-DRB1*15.39,41,42 
Dominant negative epistasis (the phenomenon that the effects of a gene are modified by 
one or several other genes) is also seen in the HLA region, as HLA-DRB1*14 completely abrogates any 
risk associated with HLA-DRB1*15, when they are inherited together.39-41,43 The relative risk of MS for 
an individual who carries the HLA-DRB1*15 allele is about 3. HLA-DRB1*14 together with HLA-DRB1*15 
reduces the relative risk to approximately 1.41 HLA-DRB1*11 bearing haplotypes are protective as well. 
The protective effect of this haplotype over HLA-DRB1*15 is weaker than that of HLA-DRB1*14.41 
While HLA-DRB1*11 and  HLA-DRB1*14 have an independent protective effect, HLA-DRB1*01 
and HLA-DRB1*10 are only protective in the presence of HLA-DRB1*15,39,41 although reports from Sweden 
suggest that HLA-DRB1*01 may be protective on its own.44  
HLA-DRB1*08 shows the opposite trend as it increases MS risk only in the presence of HLA-
DRB1*15.39,41,43 In the figure, the relative risks of MS for combinations of alleles at the HLA-DRB1 locus is 
shown.39,41,43
Furthermore, there is some evidence for epigenetic effects in the HLA region in MS. Using the 
large Canadian database, it has been possible to analyse affected aunt/uncle-niece/nephew (AUNN) 
pairs. The HLA-DRB1*15 frequency in affected males remained the same over the two generations, 
whereas affected aunts had significantly lower HLA-DRB1*15 frequency compared with their affected 
nieces. The risk carried by HLA-DRB1*15 was greater in families with affected second-degree relatives 
(AUNN: odds ratio (OR) 4) when compared to those consisting of only affected first-degree relatives 
(affected sibling pairs (ASP): OR 2). Thus, HLA-DRB1*15 contributed to risk in both family types, however 
the degree of contribution is not the same and is dependent on family structure and of MS status of the 
relatives of the transmitting individual. The exact reason for this is yet to be determined; however, gene-
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environment interactions are implied.45 Moreover, the observations demonstrate that the human MHC 
is directly involved in the increasing MS incidence in females, suggesting that the MHC is the site of a 
gene-environment interaction central to disease susceptibility.
Figure 1 Genotyping relative risks for MS for combinations of alleles at the HLA-DRB1 locus
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Data derived from HLA-DRB1 genotyping performed by the Canadian Collaborative Study Group, comprising 2,535 individuals with 
definite MS and 4,799 of their unaffected first- degree relatives. x/x=individual with no disease associated alleles with baseline risk of 
1, x= any non-disease associated allele; 15, 17, 11, 08, 14, 10, 01-HLA-DRB1 alleleles. All genotypes are statistically significantly different 
from baseline, except for HLA-DRB1*14/15 and HLA-DRB1*11/17. No HLA-DRB1*14 homozygotes were observed, and it should be noted 
that HLA-DRB1*10 and 01 provide greater protection against HLA-DRB1*15 than HLA-DRB1*14.
(figure provided by S. Ramagopalan and G.E. Ebers)43
Environmental factors and the HLA region
Little is known about gene-environment interaction. There is some evidence that vitamin D and 
infectious mononucleosis (IM) influence the risk associated with HLA-DRB1*15. Epidemiological studies 
provided strong evidence that the geographical distribution of MS risk is the result of environmental 
factors operating at the population level. Sunlight, specifically through its role in generating active 
vitamin D, is a likely important environmental factor for the disease.4,46,47 It has been shown that dietary 
vitamin D intake reduces disease risk46 and that MS patients are deficient in vitamin D.47 Vitamin D has 
its actions on immune and central nervous system development and function. Thus vitamin D could 
influence MS risk in this way.
Most biological effects of vitamin D are regulated by the vitamin D receptor (VDR). This 
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receptor influences the rate of transcription of vitamin D responsive genes by acting as a ligand activated 
transcription factor that binds to vitamin D response elements (VDREs) in gene promotors. Using 
sequence analysis, Ramagopalan and colleagues localized a single  VDRE to the promotor region of HLA-
DRB1.48 Sequencing of this promotor in more than 1,000 chromosomes from HLA-DRB1 homozygotes 
showed conservation of this VDRE on HLA-DRB1*15. In contrast, among non-MS associated haplotypes, 
there was striking variation.48 
In addition, a functional role for this VDRE was demonstrated.48 B cells transiently transfected 
with the HLA-DRB1*15 gene promotor showed increased expression upon stimulation with 
1,25-dihydroxyvitamin D3 (P =0.002), that was lost either upon deletion of the VDRE or with homologous 
VDRE sequence found in non-MS-associated HLA-DRB1 haplotypes.48 
Additionally to vitamin D, interactions may exist with Epstein-Barr virus (EBV) induced IM. 
Epidemiological and serological studies already showed that infection with EBV is associated with 
higher risk of MS.49,50 In particular, primary EBV infection, manifestating as IM seems to be associated 
with increased MS risk.
In a Danish study in IM-naive individuals, DRB1*15 carried a 2.4-fold (95% confidence interval 
[CI], 2.0-3.0) increased MS risk, whereas in persons with IM history DRB1*15 was associated with a 7.0-fold 
(95% CI, 3.3-15.4) increased MS risk. Thus, the MS risk conferred by HLA-DRB1*15 was 2.9 (95% CI, 1.3-6.5)-
fold stronger in the presence than in the absence of a history with IM.51 
Non-HLA MS risk single nucleotide polymorphisms 
There are different reasons why until very recently no other risk genes than the HLA risk gene were 
identified. The attributable risk of other risk alleles is very small. Another reason is the heterogeneity of 
the populations studied. Undoubtedly the most important factor is the lack of power. 
To overcome the problem of statistical power, the International MS Genetics Consortium 
(IMSGC) performed a genome-wide association study (GWAS). In the screening phase of this study more 
than 300,000 single nucleotide polymorphisms (SNPs) were tested in 931 families. For the replication 
phase 110 SNPs were selected and genotyped in another set of more than 2,500 MS patients and 
controls. Finally, a combined analysis was performed. 
For 17 SNPs located in 14 regions an association with susceptibility for MS was identified. Only 
two regions, HLA-DR  and IL2RA, achieved genome-wide significance (P <5 x 10-08).52 For a third gene, IL7R, 
already singled out as a strong candidate gene,53-56 convincing functional support was obtained.58 Later 
genome-wide significance was established in a joint analysis of 11,019 patients and 13,616 controls.59 It 
is of note that the three risk sequence-allelic variants are all common variants.
Follow-up studies and further genome-wide analyses have now provided genome-wide 
significant support for several non-HLA MS risk genes: IL7R, IL2RA and KIF1B,60  CLEC16A (KIAA0350)61-
63, CD226 (DNAX accessory molecule 1[DNAM-1]),61 CD58,63 CD6,64 IRF8 (ICSBP1), 64 TNFRSF1A,64 a locus 
on chromosome 12 most probably relating to the gene CYP27B1,65, 66 TYK2,67-69 STAT3,70 KIF21B,71, 72 and 
TMEM39A.71
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From genes to pathogenesis
The identification of risk genes for MS can help us in understanding the biological pathways involved 
in MS. It is important to recognize that their individual contribution is at present of no clinical value, 
because each identified risk variant is a common variant in the general population and their contribution 
in MS risk is very small. 
It should be stressed that all associations discovered are at the SNP level. Sometimes they are 
situated in intronic areas or inside the gene desserts. For most of the SNPs a causative pathway remains 
to be determined. Most of the above immune related SNPs (see also the discussion of this thesis) have 
overlapping associations with autoimmune conditions such as rheumatoid arthritis, inflammatory 
bowel disease, SLE, Type 1 diabetes and thyroid autoimmunity (Table 1). This suggests that in MS and 
other autoimmune diseases, common pathways are involved in pathogenesis.
Table 1 Overlapping associations of risk genes for MS with other autoimmune diseases 
Gene Chr Function Disease Reference
IL7R 5 Homeostasis of the memory T-cell pool, T1D, chronic inflammatory 
arthropathies
73,74
IL2R 10 Regulation of T-cells T1D, GD
RA, JIA
75-78
CLEC16A 16 Provides signals for decisions between tolerance and 
immunity
Addison’s disease, T1D, CD, 
JIA, RA, AITD 
60,79-82
CD226 18 Adhesion and co-stimulation T-cells T1D, RA, AITD
CED, Wegener’s 
granulomatosis 
73,83-89
CYP27B1 12 Hydroxylates 25-hydroxyvitamin D into the bioactive form T1D, Addison’s disease 90-92
TNFRSF1A 12 Influences the TNFa pathway Tumor necrosis factor 
associated periodic 
syndrome (TRAPS), IBD, 
persistent palindromic 
rheumatism
93-95
CD58 1 Influences T-cell proliferation and differentiation RA, chronic inflammatory 
polyneuropathies?
96, 97
TYK2 19 Signalling by type I interferons and induction of Th1 cell 
differentiation upon antigen stimulation of dendritic cells
SLE 98
STAT3 17 Involved in multiple pathways and functions, including 
the Jak-STAT pathway, neuron axonal guidance, apoptosis, 
activation of immune responses and Th17 cell differentiation
CD, UC, 
hyperimmunoglobulin 
E recurrent infection 
syndrome (HIES) 
99-102
KIF21B 1 Involved in axonal transport, also expressed in a variety of 
autoimmune cells
IBD 99
Abbreviations: AITD, autoimmune thyroid disease; CED, celiac disease; CD, Crohn’s disease; GD, Graves’disease; IBD, inflammatory 
bowel disease; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; TID, Type 1 diabetes; UC, ulcerative colitis.
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Scope of this thesis
The objective of this thesis was to find new risk alleles for MS. This may finally result in a better 
understanding of the pathogenesis of MS. Knowledge of MS disease pathways can direct strategies for 
prevention, diagnosis and therapy. In our study, we included MS patients from a genetically isolated 
population in the southwest of the Netherlands. We followed this strategy because of the relative 
genetic homogeneity of an isolated population and because relationships are known between patients. 
In chapter 2 we assessed whether MS patients from this population were more often related to each 
other compared to controls from the same population. We investigated the parental relationship of 
MS patients using extensive genealogical information available from the Genetic Research in Isolated 
Populations (GRIP) program in chapter 3. In chapter 4, the results of two replication studies of the 17 
by the IMSGC identified risk SNPs are described. In chapter 4.1, we verified the association of the 17 
risk SNPs in MS patients and controls from the genetically isolated population. The second replication 
study (chapter 4.2) was performed in three independent cohorts: from the Dutch genetically isolated 
population, from the Dutch general population, and from the Canadian Collaborative Project on the 
Genetic Susceptibility to MS. The results were pooled with those of a recently published Australian 
replication study and with those of the original IMSGC study. Finally, we conducted a GWAS in the isolate 
and replicated the results in four independent cohorts, as reported in chapter 5. In the last chapter 
(chapter 6), we reflect our main findings, discuss methodological issues, speculate on the implications 
of our results and propose future studies. 
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Abstract
Multiple sclerosis (MS) is a complex disease with a substantial, yet poorly identified genetic influence. 
We estimated the pattern of familial aggregation of MS in a recent genetically isolated population in 
the Netherlands. Forty-eight MS patients were identified. Their relationship was evaluated by tracing 
extended pedigrees, making use of municipal and church records. Of the 48 MS patients, 24 could be 
linked to a common ancestor in 14 generations. However, multiple relationships exist between patients 
and to take these into account we calculated inbreeding and kinship coefficients. We found that MS 
patients from the isolate were significantly more often related to each other and significantly more often 
inbred than a non-MS control group, drawn from the same isolate. There was no clustering of Type 1 
diabetes and autoimmune thyroid diseases in families of MS patients from this isolate. Finally, HLA typing 
was performed. Although there was a trend towards a higher prevalence of the HLA DRB1*15 allele 
in patients compared to controls, differences did not reach significance. This study suggests familial 
aggregation in the genetically isolated population. The high level of inbreeding makes this population 
valuable for finding novel genes involved in MS.stic enrichment of susceptibility genes, make this 
population valuable for finding novel gene
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Introduction
Although familial aggregation of multiple sclerosis (MS) has long been recognized,1,2 thus far, the mode 
of inheritance remains unclear. 
Some studies suggested that a single genetic abnormality might be sufficiently severe to result 
in a form of inheritance following a Mendelian pattern. An autosomal dominant mode of inheritance of 
MS with reduced penetrance has been proposed for one family.3 Autosomal recessive inheritance has 
been suggested in other studies,4,5 but either mode of inheritance remains unproven. In the majority of 
patients, MS is probably the outcome of the additive effects of multiple genes with complex gene-gene 
and gene-environment interactions.
Data in most studies on family aggregation of MS have been based on interview-based 
information on family history. For distantly-related persons, data may be difficult to reproduce in this 
way. Availability of genealogical information over multiple generations is needed to unravel distant 
relationships. Such information is usually available in isolated populations, eg, in Italy,6 Iceland,7 and 
Northern Sweden.8 Studying familial aggregation and constructing extended and multigenerational 
pedigrees becomes possible when well-documented genealogical records are available. 
The presence of inbreeding, which may reveal recessive forms of disease, can be more easily 
assessed in the extended pedigrees than by patient interview only, especially when patients are related 
more than a few generations ago. 
Of interest is the recent finding of clustering of MS with other autoimmune disorders, 
including Type 1 diabetes and thyroid disease.9-11 Another striking feature in the Sardinian population is 
that the risk of MS is not associated with the HLA-DRB1*15 allele,12 but rather with the HLA-DRB1*03 and-
DRB1*04 alleles.13,14 The HLA-DRB1*03 allele is also associated with an increased risk of Type 1 diabetes.10,15 
This association may partly explain the familial clustering with Type 1 diabetes, although other genetic 
factors also appear to play a role.16
The purpose of this study was to investigate the pattern of familial aggregation of MS in 
a genetically isolated population in the Netherlands. We studied both clustering of MS patients in 
families and clustering of MS, Type 1 diabetes and autoimmune thyroid disease. We tested if the clinical 
characteristics of the MS patients from the isolate were different from patients from outside the isolate. 
To determine if the HLA distribution in this population is comparable with the HLA distribution in a 
control group from the same isolate we performed HLA typing. 
Material and methods
Study population
MS patients were identified in a genetically isolated community in the southwest of the Netherlands. This 
population is studied as part of the ‘Genetic Research in Isolated Populations’ (GRIP) program. About 150 
individuals founded the GRIP population around 1750. Until recently, this population was characterized 
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by minimal inward and outward migration. During the last two centuries, this population underwent an 
exponential growth. Currently, the population consists of >20,000 individuals.17 
Patients
Patients were traced through local general practitioners. The Medical Ethics Committee of the Erasmus 
Medical Center Rotterdam, the Netherlands, approved the study protocol.  
 Fifty-four individuals, diagnosed with multiple sclerosis, were identified in this genetically 
isolated population. Forty-five patients were traced by their general practitioner. Six patients were 
presented by their relative with MS. Two patients were traced by the genealogist and one patient, 
living in the area, by a routine visit at the outpatient clinic of our MS Centre.
Of the 54 identified individuals with MS, 50 subjects (15 male, 35 female) agreed to participate 
in the study. After written informed consent was given, all medical records, as well as MRI scans of 
brain and spinal cord, if available, were reviewed by at least three independent neurologists to confirm 
diagnosis. In case of discrepancy, the final diagnosis was established at a consensus meeting.
Of the 50 participating patients, 41 (85%) subjects fulfilled the criteria of Poser18 for definite MS. 
Six patients fulfilled the criteria for clinically probable and one for laboratory supported MS. Two male 
patients were excluded from this study, one because he was diagnosed with CADASIL instead of MS, 
and the other because he did not fulfill MS criteria after thorough revision of the clinical data. Therefore, 
48 MS patients (13 male, 35 female) were analysed in this study (Figure 1). To test if age at onset and 
gender distribution of these 48 MS patients were comparable to those of a standard MS population, 
we compared the characteristics of the 48 MS patients with those of a group of 73 sporadic Dutch MS 
patients, from outside the isolate.19
 
Declined participation 
(n=4) 
Participating 
(n=50) 
Other diagnosis after 
revision 
(n=2) 
 
Definite or possible 
(n=48) 
 
Multiple sclerosis 
in genetic isolated area 
(n=54)  
    MS 
Figure 1 Ascertainment of 48 MS patients in the genetically isolated population.
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Genealogical information
Genealogical data, comprising name, date and place of birth and death of relatives were obtained 
from the participants at home interviews. By means of local municipal and church registers, and a 
large genealogical database, containing information for almost 70,000 individuals, this information 
was extended up to 14 generations. This information was used to study familial clustering of MS in the 
genetic isolate.
Family history
In all patients, we carried out a questionnaire on medical history, family history and co-occurrence of MS 
and other diseases in relatives of MS patients. Special emphasis was paid on the co-occurrence of Type 
1 diabetes or autoimmune thyroid disease in MS patients and their relatives. We defined Type 1 diabetes 
in accordance with criteria reported by the Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus.20 Diagnosis of autoimmune thyroid disease in MS patients and first-degree relatives 
of MS patients was verified by medication intake, cause of thyroid dysfunction, and/ or by information 
of the general practitioner. Evident non-autoimmune causes of hypothyroidism and hyperthyroidism 
were excluded.
HLA typing
Venous blood (30 mL) was obtained for DNA isolation from each patient. Venous blood was also 
obtained from a control set, consisting of 39 spouses or close friends of 39 MS patients. Genomic DNA 
was extracted from peripheral blood leucocytes, according to a standard protocol.21
HLA-DRB1 typing was performed at the two-digit level using a commercially available typing 
system, in which exon 2 of the HLA-DRB1 gene is amplified and the amplified product is analysed with 
allele-specific probes in a line probe assay (INNO-LiPA, Innogenetics, Ghent, Belgium). This resulted in the 
determination of the allele groups DRB1*1, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18.22
Statistical analysis
We performed general descriptive statistics using c² statistics for dichotomous variables and a Student’s 
t-test for continuous variables. Kinship and inbreeding coefficients were calculated, using PEDIG 
software,23 based on the genealogical information of the total population, consisting of 74,461 subjects. 
Genealogical relationships were expressed as the pairwise kinship coefficient. This is the 
probability that a randomly drawn allele from one person is identical by descent with a randomly 
drawn allele at the same locus from the other person. If individuals are related to each other, the kinship 
coefficient is higher than zero, if not, the kinship coefficient is equal to zero. 
Inbreeding coefficients were also calculated. The inbreeding coefficient is the probability 
that two alleles at the same locus in an individual are identical by descent and represents the degree 
of consanguinity between parents of an individual. The presence of consanguinity in affected people 
may point to the presence of a recessive mutation underlying the disease. Inbred individuals have an 
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inbreeding coefficient higher than zero, while the inbreeding coefficient is zero for those who are not 
inbred.
To evaluate familial clustering of MS patients, we considered only the patients who were 
probands, ascertained through the general practitioner. We excluded the patients that were identified 
via their relatives or by the genealogist. We also excluded MS patients who were born outside the isolate. 
Genealogical information for this population is only available for people born in the isolate. The inclusion 
of patients who were born outside the isolate could result in false low kinship coefficients, because of 
the lack of genealogical information for these subjects. Thus, only 17 MS patients were included for 
calculation of kinship and inbreeding coefficients. Of these 17 probands, 13 probands were members 
of the large pedigree. 
Further, we studied whether kinship and inbreeding values in the 17 MS patients deviate from 
what might be expected in a random sample of individuals in the isolated population. The random 
samples of individuals, drawn from the genealogical database, were matched by age, sex and place 
of birth with the 17 MS patients. We performed 1,000 replicas of this sampling in order to obtain a null 
distribution for the kinship and inbreeding coefficients. P-values were computed using bootstrapping.
Results
Patients
In total, 48 MS patients participated in the study. General descriptives of the participants are presented 
in Table 1. We found no significant differences between age of symptom onset and gender of the 48 
MS patients and age of symptom onset and gender of a group of 73 sporadic Dutch MS patients, from 
outside the isolate.19
Table 1  Description of the total study group, MS patients that could be and could not be linked to a common 
ancestor
Variables MS patients
(n=48)
MS patients with common 
ancestor (n=24)
MS patients, no common 
ancestor (n=24)
Age
    Of onset symptoms
    Of diagnosis
32 ± 11
38 ± 12
29 ± 9
36 ± 11
35 ± 12
41 ± 12
Sex
    Female (%) 73 79 67
Clinical phenotype at onset
    Relapse-onset (%)
    Primary progressive (%)
85
15
83
17
88
13
Dichotomous variables are expressed as percentage. Values of continuous variables are expressed as mean ± standard deviation.
Genealogy
Eleven (23%) of the 48 MS patients reported that they did have a first- or second-degree relative with 
MS. After an extensive genealogical analysis, we found that 24 of 48 MS patients (50%) could be linked 
to one common ancestor in 14 generations. Figure 2 shows the genealogical lineages of the patients 
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of the pedigree. Numerous connections exist between these patients via multiple ancestors. General 
descriptions for the 24 MS patients, who are in the pedigree, are presented in Table 1 as well as the 
general characteristics for the 24 MS patients who are not in the pedigree.
 
Figure 2 Pedigree of 24 MS patients and their relationships to a common ancestor. White solid squares indicate 
males, white solid circles indicate females. Black dots indicate meiosis. Diamonds indicate the MS patients.
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The average age of onset of symptoms for the 24 related patients was lower than for the 
24 non-related patients, with borderline significance (P =0.05). Clinical phenotype, regarding age of 
diagnosis, gender and disease course,24 did not show a significant difference between patients of the 
pedigree and patients that could not be linked to a common ancestor. When we compared the 24 
related MS patients with the 73 sporadic Dutch MS patients,19 from outside the isolate, we could not 
find a significant difference between age of symptom onset (P =0.57). In addition, gender was equally 
distributed amongst these two groups.
We tested, by calculating kinship coefficients, whether the 17 MS probands born in the isolate 
were more closely related than controls, who were matched for sex, age and place of birth and who 
were randomly drawn from the genealogical database. This analysis showed that 95% of MS patients 
were related to each other, compared to 34% expected in the random group (P <0.0001) (Table 2). In 
addition, significantly more MS patients could be linked to a common ancestor (88%) than expected by 
chance (49%, P <0.0001).
Table 2 Distribution of kinship coefficients for patients and controls
Kinship Coefficient MS probands Controls
> 0 129 (95)* 45,803 (34) 
0 7 (5)* 90,197 (66) 
Total number of pairs 136 (100) 136,000 (100)
All values are absolute numbers with percentages of the total number of pairs in brackets.
*  Significantly different from controls (P <0.0001).
We further calculated the inbreeding coefficients for patients and randomly selected controls. 
The percentage of MS patients with inbreeding was 82%, compared to 36% for the control group, which 
was significantly higher (P <0.0001) (Table 3). 
Table 3 Distribution of inbreeding coefficients for patients and controls
Inbreeding Coefficient MS probands Controls
> 0 14 (82)* 6,172 (36) 
0 3 (18)* 10,828 (64) 
Total numbers 17(100) 17,000 (100)
All values are absolute numbers with percentages in brackets.
*  Significantly different from controls (P <0.0001).
Type 1 diabetes and thyroid disease
None of the 48 MS patients was also diagnosed with Type 1 diabetes. The 48 MS patients had a total of 361 
first-degree relatives. Type 1 diabetes was reported in two of the 361 (0.6%) first-degree relatives, which 
is very similar to the prevalence of about 0.4% in the general Dutch population (www.diabetesfonds.nl).
Familial clustering of multiple sclerosis in a Dutch genetic isolate
31
Chapter
 2
Only one of the 48 MS patients was diagnosed with an autoimmune thyroid disease. 
Seven out of the total of 361 (1.9%) first-degree relatives had a thyroid disease, reportedly due to an 
autoimmune disease. Prevalence of thyroid disease seems to be similar to that observed in the English 
population (about 25%).25 There is no information about prevalence of autoimmune thyroid disease 
in the Netherlands. Families with no co-occurrence of autoimmune diseases did not differ in clinical 
characteristics from families with co-occurrence of such ailments. 
HLA typing
Figure 3 shows the HLA allele distribution in cases and controls. Allele and genotype proportions in MS 
patients and controls did not deviate from Hardy-Weinberg equilibrium (P =0.988 and 0.997 respectively). 
The HLA-DRB1*15 allele was not found significantly more often in MS patients (28% of 96 alleles) than in 
controls from the isolate (18% of 78 alleles) (OR: 1.79; 95%: 0.86-3.71; P =0.12). Additionally, we did not 
find significant differences between cases and controls for the other HLA-DRB1 alleles.  
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Figure 3 Distribution of HLA-DRB1 alleles among MS patients and controls.
Discussion
In this study, we identified 48 MS patients in a genetically isolated area in the Netherlands. Twenty-
four (50%) of the 48 patients could be linked to one common ancestor, thus providing the largest MS 
pedigree reported so far. There were no special clinical features seen in these patients, compared to the 
general population, including age of onset. Previous studies have shown that patients with evidence for 
strong genetic loading for MS tend to have earlier onset of the disease.26 The age of symptom onset of 
MS patients who could be linked to a common ancestor was lower than the age of symptom onset of MS 
patients who could not be linked to a common ancestor, although just reaching borderline significance. 
Age of symptom onset did not reach significant differences between patients of the pedigree and a set 
of sporadic MS patients from our outpatient clinic. A slight skew towards females was found for patients 
who could be linked to a common ancestor (79%), not reaching significance.
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An increased relation to a common ancestor, as well as kinship between patients indicates 
familial clustering of the disease. Familial clustering of MS was also found in a northern Swedish rural 
district8 and in the isolated population of Sardinia.27 Within the pedigree we observed a substantial 
amount of inbreeding, and we calculated that there were significantly more MS patients with inbreeding 
in this population, compared with controls from the same population. This could be in line with an 
autosomal recessive mode of inheritance, at least in a subset of patients. However, at this stage in our 
study, we cannot exclude the presence of susceptibility genes for which homozygosity shows the 
highest increase in risk. Both models may be detected by homozygosity mapping. Identification of the 
gene involved will ultimately reveal the true mode of inheritance. 
We examined the co-occurrence of autoimmune disease in MS families, since this was an 
important feature in the Sardinian isolate,10 and, to a lesser extend, also observed in the UK.9 In total, 0.6% 
of all 361 first-degree relatives were reported to have Type 1 diabetes. In the Netherlands, a prevalence of 
about 0.4% for Type 1 diabetes mellitus is reported by the national diabetes fund (www.diabetesfonds.
nl). Therefore, in contrast to the isolated population in Sardinia, the prevalence of Type 1 diabetes in the 
first degree relatives of the MS patients does not appear to be enhanced in this isolated population (P 
=0.6).
In total seven out of 361 (1.9%) first degree relatives were reported to have a thyroid 
autoimmune disease. A population-based study for the prevalence of thyroid disease in the north of 
England was carried out by Tunbridge et al.25 The prevalence of thyroid disease was about 2.5% . Only 
patients with an abnormal function of the thyroid gland were included for calculation of the prevalence 
of thyroid disease and not only autoimmune thyroid diseases. By far the highest percentage of thyroid 
diseases with an abnormal function of the thyroid gland is due to autoimmune thyroid diseases in the 
UK and the Netherlands. Therefore, the percentage we observed in the isolated population does not 
appear to differ much from what is found in the general population. Thus, in contrast to MS families from 
the UK, the prevalence of autoimmune thyroid disease in the first degree relatives of the MS patients also 
does not seem to be high in this isolated population.
Several studies have shown association of MS with the HLA-DRB1*15 allele. Also, in a large North 
American pedigree, linkage of this allele with another susceptibility locus on 12p12 has been suggested 
to be important for development of MS.28 In our isolated population, although a trend towards a slightly 
higher prevalence of the HLA-DRB1*15 allele was found, differences did not reach significance. This can 
probably be explained by the low numbers of patients and controls in whom HLA has been genotyped. 
The prevalence of HLA-DRB1*15 is more similar to that in local controls. This finding is in accordance with 
findings in a genetically isolated population in Northern Sweden, where no significant sharing of the 
HLA region was found.29 In the Sardinian genetic isolate, there was no association of the HLA-DRB1*15 
allele with the MS population. In that area HLA-DRB1*03 and HLA-DRB1*04 are over-represented along 
with an increased incidence of Type 1 diabetes.10,14,15 The fact that we also did not find any indication 
for over-representation of HLA Class II loci in our population supports the view that other loci outside 
the MHC region are shared by individuals with MS in this population,16 such as observed in the northern 
Familial clustering of multiple sclerosis in a Dutch genetic isolate
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Sweden isolate.29 Here, a novel susceptibility gene for MS was suggested in chromosome 17p11. We 
conclude that extensive genealogical search in this genetic isolate revealed a large proportion of MS 
cases, which were linked in a genetic way. The extended pedigree may prove to be helpful for identifying 
the genes involved, using an autosomal recessive inheritance model. Given the lack of several special 
clinical characteristics in this MS population, the genetic pathways involved could have relevance for MS 
in the general population.
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Abstract
Objective: To investigate the parental relationship of patients with multiple sclerosis (MS) from an 
extended pedigree with extensive genealogical information up to the middle of the 18th century.
Design: Multiple sclerosis is a complex disease resulting from genetic and environmental factors. Parent-
of-origin effect, a phenomenon when the same allele may express differently depending on the sex of 
the transmitting parent, may influence the risk for MS. We investigated parental relationships between 
patients with MS using extensive genealogical information available from the Genetic Research In 
Isolated Populations (GRIP) program. We compared the average kinship of the parents of MS patients. 
We further explored the distribution of shortest genealogical links between parents of MS patients.
Subjects: Twenty-four MS patients from the isolated population who could be linked within a large 
complex pedigree, including 2,471 people in total.
Results: The results consistently indicate a higher prevalence of maternal transmission of MS. The kinship 
between mothers of patients was 3.8 times higher than that between fathers (bootstrap P =0.01). Among 
the 814 shortest connections between parents, 333 were maternal (41% versus 25% expected), 98 were 
paternal (12% versus 25% expected), and 383 were maternal-paternal (47% versus 50% expected) (P 
<0.001). 
Conclusions: Mothers of MS patients were more closely related than their fathers. This skewed relationship 
shows evidence for a maternal effect in MS. The most likely explanation is a gene-environment effect 
that takes place in utero.
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Introduction
Multiple sclerosis (MS) is a complex disease resulting from the interplay between both genetic and 
environmental factors. Genetic factors are implicated to play a role in determining MS risk by adoption 
studies,1 studies with half-siblings,2 twin studies3 and studies of conjugal MS.4 Migration studies, have 
especially pointed to environmental factors as playing a role in MS.5,6 
Other influences, as parent-of-origin effects, are also described in determining MS risk. Parent 
of origin is a phenomenon when the same allele is expressed differently depending on the sex of the 
transmitting parent. A study of half-siblings showed that maternal half-siblings have significantly higher 
risk of developing MS compared with paternal ones, suggesting a maternal parent-of-origin effect.2 In 
contrast, observations in offspring of affected parents demonstrated excess of paternal vs maternal 
transmission.7
Both studies in which a parent-of-origin effect in MS was suggested were performed in 
differentially selected patient groups: with nonaffected parents in the study by Ebers et al2 and affected 
parents in the study by Kantarci et al.7 They had in common that only recent generations of patients with 
MS were studied.
We studied parent-of-origin effects of MS transmission in a genetically isolated population, 
with extensive genealogical information over centuries. Most cases were not closely related but were 
initially diagnosed as sporadic MS cases. The clinical MS phenotype was similar to MS in the general 
Dutch population.8
Methods
Study population and patient ascertainment
This study was performed within the framework of the previously described Genetic Research in Isolated 
Populations (GRIP) program.9,10 The Medical Ethics Committee of the Erasmus MC approved GRIP 
protocols. The GRIP population is a genetically isolated community in the southwest of the Netherlands. 
Fewer than 400 individuals founded the population in the middle of the 18th century. Considerable 
population growth subsequently occurred. Until recently, there was minimal immigration. An estimated 
20,000 descendants of this population are scattered over eight adjacent communities. The genealogical 
database contains information on more than 90,000 people spanning 23 generations. Residents in the 
GRIP area are generally related via multiple lines of descent.
Ascertainment and clinical characteristics of MS patients in the GRIP population have been 
described in detail previously.8 In brief, 24 MS patients (5 men and 19 women) could be linked to the 
most recent common ancestor in 14 generations. These 24 MS patients had given written informed 
consent. Numerous connections exist between these patients via multiple common ancestors.
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Parent-of-origin effect
We compared average kinship of parents of the 24 MS patients, testing whether patients were more often 
related through paternal or maternal lineage. Kinship coefficients were computed using a computer 
software package (PEDIG).11 Under the null hypothesis of no parent-of origin effect, the average degree 
of relationship of fathers should not be different from the one of mothers, assuming random mating.
When there is deviation from random mating (in particular, preferential outbreeding for one 
of the sexes), the test based on comparison of average kinships between mothers and fathers is not 
correct. For example, if there is systematic outbreeding of males, one would expect to observe higher 
kinship between mothers of any randomly selected group of people from the population. 
To assess the empirical null distribution of differences in parental relationship specific for 
our population, we performed analysis using 10,000 replicas. For each time, 24 individuals, adjusted 
for sex and age with the patients, were randomly sampled from the GRIP genealogy database. This 
procedure is also known as bootstrap. Average kinship was computed for fathers and mothers of these 
randomly sampled individuals, and the ratio between maternal and paternal kinships was computed. 
The proportion of realizations in which the ratio was the observed ratio or more gives the empirical P 
value.
We further explored genealogical links between MS patients via all of their common ancestors 
using a software package (FCN; available at http://mga.bionet.nsc.ru/soft/index.html). We next focused 
on the shortest connection between patients. Under the hypothesis that a genetic factor plays a role in 
MS, one assumes that patients are more closely related to each other than control subjects. In terms of 
genealogical links, this implies that, on average, links between MS patients are shorter than that those 
between controls. For the shortest genealogical link between two MS patients there are three possible 
patterns: two patients are related through their mothers, through the father of one patient and the 
mother of the other patient, or through their fathers. Under the null hypothesis of no parent-of-origin 
effect, and assumption of random mating, the expected distribution of these three patterns is 25% 
through their mothers, 25% through their fathers and 50% through a father and a mother. A c2 test with 
2 df was used as the test statistic.
In all analyses, when siblings were present as patients, the parents were included in  paternal/
maternal samples only once to avoid possible bias.
We had the unique opportunity to test parent-of-origin effect in the same way for several 
other diseases in the GRIP area, including Parkinson disease, late-onset Alzheimer disease, and Type 1 
diabetes.
Results
The general characteristics of the 24 MS patients are as follows. Their mean (SD) age at onset of 
symptoms was 29 (9) years; at diagnosis, 36 (11) years. There was no significant (P =0.57) difference in 
age of symptom onset between the 24 MS patients and 73 sporadic Dutch MS patients from outside the 
isolate.8,12 There were 19 women (79%) in the sample. The distribution of relapse-onset MS (20 patients 
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[83%]) and primary progressive onset MS (4 patients [17%]) was not different from that in the general 
MS population. Of the 24 patients, 15 were initially diagnosed as isolated MS cases and nine were from 
families in which patients were themselves aware of having two or more MS cases in their families. Of 
these nine patients, four were affected sisters from one family, all participating in this study. The other 
five patients were from families in which two people were diagnosed as having MS: two participating 
patients were third-degree relatives, two participating patients were second-degree relatives, and one 
patient had a first-degree relative with MS who did not want to participate in this study. None of the 
parents or grandparents of the 24 patients was diagnosed as having MS.
The characteristics of the genealogy of the MS patients are as follows. The mean (SD) number 
of consanguineous loops per patient was 139.9 (278.9), with a range from 0 to 1,205; the mean (SD) 
number of meioses per loop was 12.4 (1.3), with a range from 0 to 29; and the mean (SD) inbreeding 
was 1.4 x 10-3 (1.9 x 10-3), with a range from 0 to 7.7 x 10-3. Patients with MS could be linked to multiple 
common ancestors in different generations. Each pair of patients shares, on average, 264.2 (SD, 449.4) 
common ancestors (range 2-2,936 common ancestors). The mean number of meioses separating a pair 
of patients was 22.2 (SD, 2.1), with a range from 2 to 36, which means that their common ancestry is, on 
average, 11 generations ago. The most recent common ancestor for all 24 patients could be identified 
14 generations ago. Finally,  the mean (SD) kinship for the patients was 6.7 x 10-3 (3.7 x 10-2), with a range 
from 2 x 10-7 to 0.3.
To assess the parent-of-origin effect, we compared the mean kinship of mothers and the one 
of fathers. The mean kinship of mothers (0.0031) was 3.9 times higher than the one of fathers (0.0008). A 
2-independent-samples t test comparing these kinships gives a significant P value (<0.001). The empirical 
null distribution of the ratio between maternal and paternal kinships using 10,000 samples of 24 age- and 
sex-matched controls randomly selected from our genealogical database was derived. The probability 
of observing the same or a more extreme kinship ratio in this population was P =0.01, indicating that 
closer kinship between mothers of MS patients is not a statistical artifact or a consequence of violation 
from the random mating assumption.
We further explored genealogical links between MS patients. In total 36,466 pairwise 
connections between each possible pair of 24 MS patients were identified via 796 ancestors. Among 
these connections, we counted shortest connections between each pair of MS patients in respect to the 
three possible patterns described in the : “Methods” section. Among 814 shortest connections, 333 were 
between mothers (40.9%; 25.0% expected), 98 were between fathers (12.0%; 25.0% expected), and 383 
were between a father and a mother (47.1%; 50.0% expected) (P <0.001) (Figure 1).
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333 (41%)
383  (47%)
98 (12%)
Figure 1 Observed distribution of connections between patients with multiple sclerosis (MS). Solid circles indicate 
female patients with MS; open circles, unaffected mothers of patients with MS; and open squares, unaffected fathers 
of patients with MS.
We also investigated parent-of-origin effect for several other diseases in the GRIP area, using 
the same database and the same method. For 67 patients with Parkinson disease, 103 with late-onset 
Alzheimer disease (P =0.052), and 39 with Type 1 diabetes (P =0.38) who could be linked to a common 
ancestor, no significant parent-of-origin effect could be found.
Discussion
A pedigree of 24 patients with common clinical phenotypes of MS was recently reconstructed.8
Herein, we show that the shortest connection to a common ancestor between two individuals 
with MS was significantly more often through their nonaffected mother than through their nonaffected 
father, suggesting a maternal parent-of-origin effect. No significant parent-of-origin effect was observed 
in several other diseases in the same area. Thus, the effect seems to be specific for MS.
Mothers of the 24 MS patients were also more closely related to each other than their fathers.
Multiple sclerosis has a female-male ratio of 3:1. Potentially, this carries the risk of bias when 
studying disease transmission over two generations when parents are affected and women are 
at increased risk of MS. Our approach had no bias into this skew because none of the parents and 
grandparents of the 24 MS patients were affected with MS.8 A few other studies analyzed parent-
of-origin effects, all using the information of two generations.2,7,13 The significant difference with our 
study is that by using extensive genealogical information we were able to study the shortest links by a 
multigenerational approach.
Our findings are in line with results of the Canadian study in which the difference in MS risk 
was investigated for half-siblings of MS patients with a shared non-affected parent. A shared mother was 
associated with higher MS risk.2
In contrast, a recent study in the United States observed that fathers transmit the disease more 
frequently.7 This was explained by the Carter effect. According to this theory, men are more resistant to 
MS because they require a higher genetic load  and thus are more likely to transmit the genetic risk of 
the disease to their children. This phenomenon was not observed by others.13 Our approach differed 
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from that of  Kantarci et al7 in that we did not study multiplex families and parents were not affected.
Taking together all available data on parental transmission of MS, one can conclude that the 
MS-affected status of the parent may influence transmission of disease.
Maternal transmission could be a result of several factors: genetic, environmental, or both. 
There are at least three single genetic explanations. None of them are supported heavily by current 
data. First, maternal effects could be exerted by direct transmission via mitochondrial genes or 
indirectly by autosomal genes involved in mitochondrial pathways, such as UCP2 (uncoupling protein 
2 gene) (GenBank MIM 601,693). This gene has a neuroprotective function and may contribute to MS 
susceptibility.14,15 Thus far, attempts to link mitochondrial mutations with MS susceptibility have been 
disappointing.16-18
A second possible genetic explanation is genomic imprinting.19 This has been insufficiently 
explored. 
A third explanation could be the interaction between genes and female-specific environmental 
factors, such as hormonal, intrauterine, or perinatal factors.
Recent findings have demonstrated an increasing female to male sex ratio, strongly suggesting 
an environmental origin. It seems that the relative role of environmental factors in determining MS 
susceptibility has been changed during the past century, in possible interaction with genetic factors.20
Our data show that MS patients are more often related through their mother than through 
their father, at least in the pedigree studied herein. Because MS in this pedigree has a common clinical 
phenotype and most cases were initially diagnosed as sporadic MS cases, our findings are likely to be 
representative for the total MS population. These findings support a maternal parent-of-origin effect in 
MS. There is reason to assume that this effect is caused by an interaction of genetic and environmental 
factors.21 Dense genotyping in this pedigree can help to unravel the genetic contribution, thus aiding in 
resolving the nature-nurture dilemma in MS.
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Abstract
HLA-DRB1 is the major locus associated with risk for multiple sclerosis (MS). A recent genome-wide study 
showed three additional single-nucleotide polymorphisms (SNPs), within the IL2RA and IL7RA genes 
respectively, also to be associated with MS. Consistent association but lower significance was found for 
13 other SNPs. 
In this study we aimed to verify association of these SNPs with MS in 46 MS patients and 194 
controls from a Dutch genetically isolated population. Apart form the human leukocyte antigen (HLA) 
locus, the EVI5 gene on chromosome 1 was confirmed as a novel risk gene, with odds ratios (ORs) even 
higher than those from the MS Consortium (OR 2.01 and 1.9; P =0.01). The risk effect of EVI5 was further 
validated for the general MS population in an independent set of 1,318 MS patients from the Canadian 
Collaborative Project on the Genetic Susceptibility to MS. On the basis of the transmission disequilibrium 
testing, a weak but significant risk effect was observed (OR 1.15; P =0.03 and OR 1.15; P =0.04). This 
study confirms EVI5 as another risk locus for MS; however, much of the genetic basis of MS remains 
unidentified.
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Introduction
Multiple sclerosis (MS) is a complex disease, resulting from genetic as well as environmental factors. For 
long, HLA-DRB1 has been the only locus consistently involved with higher risk for MS. Next to the human 
leukocyte antigen (HLA) region, a recent genome-wide study also showed two single-nucleotide 
polymorphisms (SNPs) within the IL2RA gene and one SNP within the IL7RA gene to be strongly 
associated with MS susceptibility. Thirteen other SNPs, although less significant, also showed evidence 
for association with MS. In total, 17 SNPs were found to be associated with MS both in the screening 
phase and the replication phase of the study, of which the SNP in the HLA region again showed the 
strongest association.1 
In this study, we assessed the risk contribution of these 17 SNPs in MS patients from a Dutch 
genetically isolated population. Apart form the HLA locus, a novel risk gene was confirmed. This finding 
is further validated for the general MS population in an independent large set of Canadian MS patients.
Patients and methods 
Participants from the Dutch genetically isolated population
This study was performed within the framework of the previously described Genetic Research in 
Isolated Populations (GRIP) program.2,3 The Medical Ethics Committee of the Erasmus MC approved GRIP 
protocols. The GRIP population is a genetically isolated community in the southwest of the Netherlands. 
The isolate was founded by less than 400 individuals around the middle of the 18th century. Minimal 
inward migration and considerable population growth subsequently occurred. An estimated 20,000 
descendants of this population are now scattered over eight adjacent communities. The genealogical 
database currently contains information on more than 90,000 people spanning 23 generations. 
Residents in the GRIP area are generally related via multiple lines of descent.
The ascertainment and clinical characteristics of MS patients in the GRIP population have 
been described in detail previously.4 Originally, 48 MS patients (13 male, 35 female) were included. Later 
on, another female MS patient was identified and included. 
All 49 MS patients (13 male, 36 female) were diagnosed according to standard diagnostic 
criteria, with regular clinical phenotypes. Although most were originally diagnosed as sporadic MS 
patients, a total of 25 (51%) could be linked to an extended pedigree.4 
Three of the 49 MS patients were excluded from analysis because they were sisters of one MS 
patient. Clinical characteristics from the 46 MS patients who were included for analysis are described in 
Table 1a. 
In this population, there was a trend towards a higher prevalence of the HLA-DRB1*15 allele in 
patients compared to controls, but no significant differences could be found (OR 1.79, P =0.12).4
For the control group, we included 194 healthy controls from the same area who were all 
distantly related (≥ 5 meioses).
All patients and controls gave written informed consent to participate in this study.
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Participants from the Canadian Collaborative Project on the Genetic Susceptibility to MS
A total of 2,825 individuals from 756 families were typed as part of the Canadian Collaborative Project 
on the Genetic Susceptibility to MS (CCPGSMS) for which the methodology has been described.5,6 This 
includes 1,318 individuals with definite MS and 1,507 of their unaffected first-degree relatives. Clinical 
characteristics from the 1,318 patients are described in Table 1b. 
 The Canadian families consisted of 456 multicase families (that is, parents with two  or more 
affected offspring) and 300 parent-child trios. 
Table 1a Description of the 46 Dutch MS patients
Variables MS patients (n=46)
Age(years)       
     Of onset symptoms
     Of diagnosis
33 ± 11
39 ± 12
Sex 
     Female (%) 72 (33)
Clinical phenotype at onset
     Relapse (%)
     Primary progressive (%) 
85 (39)
15 (7)
Abbreviation: MS, multiple sclerosis.
Table 1b Description of the 1,318 Canadian MS patients
Variables MS patients (n=1,318)
Age       
    Of onset symptoms
    Of diagnosis
31 ± 9
34 ± 10
Sex  
    Female (%) 60 (791)
Clinical phenotype at onset
    Relapse (%)
    Primary progressive (%) 
75 (989)
25 (329)
Abbreviation: MS, multiple sclerosis.
Dichotomous variables are expressed as percentage, absolute numbers in between brackets. Values of continuous variables are 
expressed as mean ± s.d.
Genotyping of individuals from the Dutch genetically isolated population
We genotyped all participants using the Affymetrix GeneChip Mapping 250K according to the protocol. 
This array set contains the Nsp array and includes approximately 262,000 SNPs. 
Genotyping of participants from the Canadian Collaborative Project on the Genetic Susceptibility 
to MS
All genotypes were generated blind to pedigree structure and disease status of the individual. 
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Genotyping of SNPs was performed using the Sequenom MassEXTEND protocol (www.sequenom.
com). Only conservative and moderate genotyping calls were accepted in this study. Samples having 
aggressive or low-probability quality genotypes were re-analysed. The concordance of genotyping 
between Affymetrix and Sequenom platforms has previously been validated.1
Statistical analyses of data from the Dutch genetically isolated population
For analysis, we used the R library GenABEL version 1.1-8.7 We used the Armitage’s test to estimate 
P-values. We used the genomic control method8 to adjust for the relationship between GRIP participants.9 
The inflation factor was estimated to be 1.28. We imputed the SNPs that were not available from the 
Affymetrix GeneChipMapping 250K Array using HAPMAP CEU haplotypes as a reference. Mach software 
was used for imputations.10,11
Statistical analysis of data from the Canadian Collaborative Project on the Genetic Susceptibility 
to MS
Transmission disequilibrium test was performed using the PLINK analysis package.12 PLINK implements 
sib-transmission disequilibrium test, which calculates empirical probabilities for c2 statistics, accurately 
reflecting association independent of linkage within families. This calculation is done by permuting 
parent alleles while fixing the identical by descent status of sibs within a family.
 The transmission disequilibrium test counts the number of times an allele is transmitted to 
affected offspring from heterozygous parents. For transmission disequilibrium tests, the c2 distribution 
was used to assess significance. The OR was calculated as described in Kazeem and Farrall.13
Results 
We tested the 17 MS SNPs that were reported to be associated in the collaborative genome-wide MS 
study (Table 2).1 The HLA-DRB1 surrogate SNP (rs3135388) was significantly associated with MS in this 
study (P =0.001, odds ratio (OR) 2.99, 95% confidence interval (CI) 1.56-5.74). Furthermore, two SNPs, both 
on chromosome 1, located in the EVI5 (ecotropic viral integration site 5) gene gave significant P-values 
in our replication study: rs10735781 (P =0.01, OR =2.01, 95% CI 1.19-3.39) and rs6680578 (P =0.01, OR 
=1.9, 95% CI 1.16-3.11). These ORs are considerably higher than those reported by the International 
MS Consortium; the confidence intervals were not overlapping. The two SNPs in the EVI5 gene were 
in nearly complete linkage disequilibrium (D’ =0.99). The IL7RA rs689732 and for IL2RA rs12722489 and 
rs2104286, SNPs were not significantly associated with MS (Table 2).
The two SNPs located in the EVI5 gene were subsequently tested in an independent set of 756 
Canadian families containing 1,318 MS patients. Both SNPs had a weak but significant contribution in 
this population (rs10735781: P =0.03, OR =1.15, 95% CI 1.01-1.30; rs6680578: P =0.04, OR =1.15, 95% CI 
1.01-1.30) (Table 3) and were in nearly complete linkage disequilibrium (D’ =0.98).
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Table 2        Results of replication analysis of 17 SNPs reported to be associated with MS in a Dutch genetically isolated 
population
Rs Chr Gene Risk 
allele
NEJM, GWA GRIP replication
RAF  OR 95% CI P Imputed RAF OR 95% CI P
rs3135388 6 HLA-DRA A 0.23 1.99 (1.84-2.15) 8.94x10-81 Yes 0.14 2.99 (1.56-5.74) 0.001
rs12722489 10 IL2RA C 0.85 1.19 (1.08-1.31) 4.56x10-4 No 0.89 1.45 (0.70-3.03) 0.32
rs2104286 10 IL2RA T 0.75 1.16 (1.08-1.25) 1.49x10-4 Yes 0.79 1.23 (0.47-3.25) 0.67
rs6897932 5 IL7R C 0.75 1.18 (1.09-1.27) 2.75x10-5 Yes 0.7 1.34 (0.79-2.29) 0.28
rs6498169 16 KIAA0350 G 0.37 1.16 (1.09-1.24) 1.89x10-5 No 0.31 1.11 (0.62-1.96) 0.73
rs6604026 1 RPL5 C 0.29 1.13 (1.05-1.22) 9.58x10-4 No 0.28 0.87 (0.51-1.49) 0.61
rs10984447 9 DBC1 A 0.77 1.14 (1.05-1.24) 1.27x10-3 No 0.78 0.83 (0.47-1.49) 0.54
rs12044852 1 CD58 C 0.92 1.2 (1.07-1.35) 2.06x10-3 Yes 0.89 0.97 1
rs7577363 2 ALK A 0.03 1.34 (1.11-1.62) 3.15x10-3 Yes 0.05 0.67 (0.14-3.26) 0.62
rs7536563 1 FAM69A A 0.38 1.08 (1.01-1.16) 2.17x10-3 No 0.40 1.18 (0.72-1.93) 0.51
rs11164838 1 FAM69A C 0.57 1.09 (1.02-1.16) 1.30x10-2 No 0.52 1.38 (0.83-2.30) 0.22
rs10975200 9 ANKRD15 G 0.18 1.11 (1.02-1.21) 2.12x10-2 No 0.16 1.77 (0.94-3.33) 0.08
rs10735781 1 EVI5 G 0.38 1.08 (1.01-1.16) 2.01x10-2 No 0.33 2.01 (1.19-3.39) 0.01
rs6680578 1 EVI5 T 0.38 1.09 (1.01-1.16) 1.86x10-2 No 0.31 1.9 (1.16-3.11) 0.01
rs4763655 12 KLRB1 A 0.38 1.09 (1.01-1.16) 1.83x10-2 No 0.34 1.11 (0.62-1.99) 0.72
rs12487066 3 CBLB T 0.73 1.08 (1.00-1.16) 3.53x10-2 Yes 0.66 0.9 1
rs1321172 1 PDE4B C 0.49 1.07 (1.01-1.14) 3.95x10-2 Yes 0.51 0.58 (0.31-1.08) 0.08
Abbreviations: Chr, chromosome; CI, confidence interval; GRIP, Genetic Research in Isolated Populations; MS, multiple sclerosis; OR, 
odds ratio; SNP, single nucleotide polymorphism.
Table 3 Results of replication of the two SNPs located in gene EVI5 in a Canadian cohort
 
SNP Risk allele TR:NT Odds Ratio
(95% CI)
c2 P 
asymptotic
rs10737581 G 510:443 1.151 4.71 0.02998
(1.014-1.308)
rs6680578 T 510:445 1.146 4.424 0.03544
(1.009-1.301)
Abbreviations: CI, confidence interval; NT, not transmitted; SNP, single nucleotide polymorphism; TR, transmitted.
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Discussion
This study replicates in a Dutch genetically isolated population, the recent indication that EVI5 is a risk 
gene for MS. Another interesting observation in the genetic isolate is that we found a very significant 
association of the HLA-DRB1*15 tagging SNP rs3135388 with MS, whereas previous extensive HLA-DRB1 
typing in this same population showed no significant association with the known HLA-DRB1*15 allele 
or other alleles at the two-digit level. A possible explanation for this may have been the lack of power in 
the initial study on this small population.4 
The study on the genetic isolate had limited power to verify the low ORs of the recent 
genome-wide study.1 The fact that we did not find statistical evidence for 14 of 17 SNPs that were earlier 
reported to be associated with MS does not exclude an effect of these SNPs/genes, as the probability 
of false-negative findings is high in this study. It is striking that despite this relatively low power, our 
study does show convincing evidence for EVI5 at chromosome 1p22 as a risk allele. This underlines the 
strength of studying genetically isolated populations in complex diseases.2,14 The ORs observed for EVI5 
are higher than the ORs reported by the International MS Consortium.1 
EVI5 was also found to be significantly associated with MS in a separate group ascertained as 
part of the  CCPGSMS. This strengthens the evidence that EVI5 is associated with MS risk. It is still not clear 
whether the causal allele acts through EVI5 itself. EVI5 is a common site of retroviral integration and has 
been linked to lymphomagenesis.15 It remains to be seen whether and to what extent it could influence 
T-cell function and also if it could be related to retroviral elements associated with MS.16 Identification 
of the exact causal allele will require the sequencing and genotyping of additional samples. In addition, 
functional immunological studies stratified according to EVI5 genotype are planned. 
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Abstract
A recent genome-wide association study by the International Multiple Sclerosis Genetics Consortium 
(IMSGC) reported association of 17 single-nucleotide polymorphisms (SNPs) in 14 loci with multiple 
sclerosis (MS). Only two loci, HLA-DRA and IL2RA, reached genome-wide significance (P <5 x 10-08). In 
our study, we determined whether we could replicate the results of the IMSGC and whether more SNPs 
are genome-wide significantly associated with MS. We assessed the association between the 17 IMSGC 
SNPs and MS in three cohorts (total number of subjects 3,981, among these 1,853 cases). We performed a 
meta-analysis of the results of our study, the original IMSGC results and the results of a recent replication 
study performed in the Australian population. Of the 17 IMSGC SNPs, five SNPs showed genome-wide 
significant association with MS: HLA-DRA (P =8 x 10-124), IL7R (P =6 x 10-09), IL2RA (P =1 x 10-11), CD58 (P =4 
x 10-09) and CLEC16A (P =3 x 10-12). Therefore, genome-wide significance has now been demonstrated 
for SNPs in different non-HLA MS risk genes. Several of these risk genes, including CD58 and CLEC16A, 
are shared by different autoimmune diseases. Fine mapping studies will be needed to determine the 
functional contributions to distinct autoimmune phenotypes.
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Introduction
Multiple sclerosis (MS) is a complex disease resulting from genetic and environmental factors. The 
genetic influence on MS susceptibility is substantial, as evidenced by the 20-fold increase in risk for 
siblings of patients. Much of the high recurrence risk is explained by the MHC Class II region.1 A recent 
genome-wide association study (GWAS)2 conducted by the International Multiple Sclerosis Genetics 
Consortium (IMSGC) reported the association of MS with 17 single-nucleotide polymorphisms (SNPs) 
located in 14 regions. Only two regions, HLA-DRA and IL2RA, achieved genome-wide significance 
(P <5 x 10-08). For a third gene, IL7R, convincing functional support was obtained2-4 and genome-wide 
significance was established in a joint analysis of 11,019 cases and 13,616 controls.5 In a recent Australian 
replication study of the 17 IMSGC risk SNPs, besides IL2RA, CLEC16A, RPL5 and CD58 were found to be 
associated with susceptibility for MS, although not genome-wide significant.6
We here assessed MS association of the 17 IMSGC reported SNPs in MS patients from a Dutch 
genetically isolated population (45 cases and 195 controls), in MS patients from the Dutch general 
population (490 MS cases and 426 controls), and in MS patients from the Canadian Collaborative Project 
on the Genetic Susceptibility to MS (CCPGSMS; 1,318 affected MS patients with their parents). In total, we 
studied 3,981 subjects, including 1,853 MS affected individuals. Results obtained in this study were also 
pooled with those obtained in the original IMSGC study2 and the recent Australian replication study.6
Material and methods
Patients and genotyping
All patients fulfilled either Poser’s criteria for definite MS or McDonald’s criteria for MS. 
The Dutch outbred cohort consisted of MS patients who are part of an ongoing nationwide 
study on genetic susceptibility in MS. A total of 490 MS patients were included, 370 sporadic MS patients 
and 120 cases from 120 multiplex MS families (that is, parents with two or more affected offspring). 
Overall, ten percent of the patients (n =51) had a clinically isolated syndrome at the time of enrollment. 
The 426 healthy controls consisted of 26 unrelated spouses, together with 400 healthy blood donors. 
Further, we have sampled 45 MS patients within the framework of Genetic Research in Isolated 
Populations (GRIP) program.7 As controls, we included 195 healthy individuals from the same area who 
were all distantly related. Details on ascertainment are given elsewhere.8 A total of 1,318 individuals with 
definite MS and 1,507 of their unaffected first-degree relatives were typed as part of the CCPGSMS.9 The 
research protocol was approved by the respective Medical Ethics Committees and written informed 
consent had been obtained.
Genotyping was carried out using the MassARRAY system/Homogeneous MassExtend assay, 
following the protocol provided by Sequenom. PCR and extension primers were designed using the 
Assay Design 3.0 program (Sequenom, San Diego, CA, USA). Briefly, 20 ng genomic DNA is PCR amplified 
using Titanium Taq DNA Polymerase (Clontech, Mountain View, CA, USA). PCR primers were used at 100 
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nM final concentrations for a PCR volume of 10 ml. The PCR condition was 95°C for 15 min, followed by 
denaturing at 94°C for 20 sec, annealing at 56°C for 30 sec, extension at 72°C for 1 min for 45 cycles and 
finally incubation at 72°C for 3 min. PCR products were first treated with shrimp alkaline phosphatase 
(Sequenom) for 20 min at 37°C to remove excess dNTPs. ThermoSequenase (Sequenom) was used 
for the base extension reactions. Analysis and scoring were performed using the program Typer 3.3 
(Sequenom).
Statistical analysis
All analyses were performed using R software (http://www.r-project.org/). Estimates of odds ratios (ORs) 
and significance were tested using logistic regression as implemented in “glm” function. Analysis was 
performed without including covariates, therefore, effectively the analysis is equivalent to the Armitage 
trend test for proportions in genotypic 2x3 table. Thus, our analysis was similar to and compatible with 
these performed in external cohorts included in this meta-analysis, in that no adjustment was done for 
covariates and allelic ORs were estimated. 
 In the genetically isolated population, over-dispersion of the standard errors was estimated 
and corrected using genomic control approach.10 Genomic control lambda was estimated as 1.37.11 
Meta-analysis of log (OR) was performed using a fixed model approach with inverse of the square of the 
estimates of standard error used as weights. Test for the heterogeneity of effects between studies was 
performed using standard Cochrane’s Q-test; random effect model was estimated using ‘rmeta’ library 
for R (by T Lumley: http://cran.r-project.org/web/packages/rmeta/rmeta.pdf ). We used a P-value of 5 x 
10-08 as the threshold for genome-wide significance.
The combined predictive value of the multiple genetic variants was investigated in a 
simulation study. The methods have been described elsewhere,12 but briefly, the simulation strategy 
creates a dataset that includes genotypes and disease status for 100,000 individuals in such way that all 
genotype frequencies and odds ratios are the same as reported in this paper and the disease prevalence 
is one in 1000. Predicted risks for all individuals are obtained using Bayes’ theorem in which the earlier 
risk of disease (1 in 1000) is multiplied by the likelihood ratios of all single variants under the assumption 
of independent genetic effects. For this reason, we included one polymorphism per gene, selecting the 
polymorphism with the strongest OR. Therefore, in total we included 14 of the 17 SNPs. We examined the 
discriminative accuracy, which is the extent to which test results can discriminate between individuals 
who will develop MS and those who will not, and is commonly assessed by the area under the receiver 
operating characteristic curve (AUC). The AUC is the probability that the test correctly identifies the 
diseased individual from a pair, of whom one is affected and one is unaffected, and ranges from 0.5 
(total lack of discrimination) to 1.0 (perfect discrimination). To obtain more robust AUC estimates, the 
simulation study was repeated 100 times and 95% confidence intervals were calculated. The AUC was 
obtained as the c-statistic by the function somers,2 which is available in the Hmisc library of R software 
(Harrell FE. Design and Hmisc R function library. Available at: http://biostat.mc.vanderbilt.edu/twiki/bin/
view/Main/RS ).
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Results 
Results of the meta-analysis are summarized in Table 1, which provides ORs and P-values for each study 
and for the combined analysis of all studies, The Supplementary Table 1 additionally provides allelic 
frequencies in cases and controls (where available) and random effect model meta-analysis. 
  The SNP rs3135388A located in the HLA-DRA region was most strongly associated with MS in 
all cohorts, as expected (Table 1). Meta-analysis, including the original IMSGC study, resulted in an OR 
estimate of 2.1 and a pooled P-value was 8 x 10-124. 
The SNP located in IL7R (rs6897932C) was consistently confirmed in the three populations 
and the meta-analysis reached genome-wide significance (P =6 x 10-09). In addition, two SNPs within 
the IL2RA gene rs2104286T and rs12722489C reached genome-wide significance. Moreover, our analysis 
established two other SNPs with genome-wide significance. For rs12044852C located in CD58 the OR 
was 1.23 (P =4 x 10-09) and for rs6498169G located in the CLEC16A locus (also named KIAA0350), the 
OR was 1.17 (P =3 x 10-12). Forest plots for these SNPs are shown in Figure 1a and b. There is some 
support in our analysis that another locus, rs10735781G in EVI5 is associated with MS (OR=1.12, P =2 
x 10-06) as independent replication was observed (Figure 1c) and the P-value of the meta-analysis 
improved compared with that reported in the initial IMSGC report. However, the overall analysis did 
not reach genome-wide significance (Table 1). Meta-analysis of SNPs in two genes that are in close 
proximity to EVI5, RPL5 and FAM69A, as well as SNPs in three other genes, ALK, CBLB and KLRB1, all did not 
change the P-values observed by the IMSGC substantially. For three loci (PDE4B, DBC1 and ANKRD15), our 
results suggest that the previously reported association in the initial IMSGC screen was a false positive 
association. 
Among genome-wide significantly implicated variants, two (rs6897932 at IL7R and rs3135388 
at HLA-DRA) showed nominally significant heterogeneity (Table 1). The source of heterogeneity for 
rs6897932 may be the data of the Australian study, which shows risk allele OR which is opposite (though 
not significant) to other studies. For the rs3135388, the heterogeneity may be introduced by the original 
study,2 which shows relatively low OR (1.99) and the Dutch isolated population, showing a relatively high 
OR (3.08). 
We calculated the AUC of the 14 genes (HLA included), found to be associated with MS by 
the IMSGC, for MS with the ORs we obtained in our meta-analysis. The AUC was 0.68 (95% confidence 
interval 0.67-0.68). The AUC for HLA alone was 0.63 (95% confidence interval 0.63-0.64), the AUC of the 
other 13 genes was 0.60 (95 % confidence interval 0.59-0.61). 
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These data further establish the genome-wide significant association with MS of six out of the 17 SNPs 
that were found to be associated with MS in a previous GWAS.2 The overall ORs of the non-HLA SNPs 
were modest, between 1.16 and 1.23. The predictive power of the 14 SNPs together was too low to have 
clinical significance, for example for diagnostic or prognostic purposes. The AUC is comparable to that 
found in recent studies on the prediction of Type 2 diabetes based on 18 susceptibility genes and on the 
genetic prediction of coronary heart disease.13 The discriminative accuracy of HLA alone was better than 
the discriminative value of the other 13 genes together (0.63 vs 0.60)
Also in the separate populations, ORs were generally below 1.30, with an exception of an 1.58 
OR for the CD58 SNP in the Dutch outbred population and an OR of 1.96 for the replicated EVI5 SNP in 
the very small population of the genetic isolate.8 This study and others found that the risk effect from the 
HLA locus is independent from the risk signal coming from the other non-HLA risk loci.2,6 
We found genome-wide significant association of rs12044852 in the CD58 gene with MS 
(overall P =4 x 10-09), which is in line with two very recent studies. The Australian and New Zealand Multiple 
Sclerosis Genetics Consortium showed genome-wide significance for the CD58 SNP rs1335532.14 This 
SNP is in strong linkage disequilibrium (LD) with rs12044852 (R2=0,93), both being located in intron 10/11 
of the CD58 gene.15 In addition, a study in MS patients from the United Kingdom and the United States 
demonstrated genome-wide significance, and further fine mapping indicated rs2300747 as the best 
susceptibility allele within the CD58 locus.16,17 Todd and colleagues recently screened the rs12044852 
SNP also in Type 1 diabetes (T1D) patients in whom it does not seem to have a role.18 CD58 encodes a 
ligand for the T-cell specific CD2 membrane molecule, an adhesion molecule that transduces important 
signals for T-cell proliferation and differentiation. In addition, a role for the CD58 molecules has been 
 
 
 
A  B C  
Association between CD58 and rs12044852[C] and MS          Association between CLEC16A rs6498169[G] and MS                  Association between EVI5 rs10735781[G] and MS
NEJM
Dutch Outbred
GRIP
Oxford
Australian
Summary
NEJM
Dutch Outbred
GRIP
Oxford
Australian
Summary
NEJM
Dutch Outbred
GRIP
Oxford
Australian
Summary
0.50     0.63      0.79     1.00      1.26      1.58     2.00                        0.79             1.00             1.26            1.58            2.00            1.00        1.26        1.58        2.00        2.51        3.16
                    OR                                          OR                          OR
Figure 1 (a) Association between CD58 rs12044852C and MS. (b) Association betweenCLEC16A rs6498169G and MS. (c) Association 
between EVI5 rs10735781G and MS. MS, multiple sclerosis. Effect estimates and 95% confidence intervals are shown. Study names: 
NEJM: IMSGC study; Dutch Outbred; GRIP: Dutch genetically isolated population; Oxford: Canadian population; Australian study.
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suggested in chronic inflammatory polyneuropathies.19 
The CLEC16A rs6498169 SNP (intron 22) was also found to be genome-wide significantly 
associated to MS when combining the Australian study6 and the IMSGC screen (P =3 x 10-08).2 Genome-
wide significance was further only noted for another SNP in this gene, the T1D-associated SNP 
rs12708716 located in intron 19 (P =1.6 x 10-16).20 In the recently published meta-analysis and replication 
study in MS patients from the UK and the US, the SNP rs11865121 in the CLEC16A gene was found 
to be associated with susceptibility to MS (P =1.77 x 10–07) in the joint analysis.17 A study in Sardinia 
that explored the contribution of T1D genes to MS risk, found association, although not genome-
wide significant, with another SNP in intron 19 rs725613 (P =4 x 10-05)21 which is in perfect LD with the 
genome-wide significantly associated SNP rs12708716 (R2=1.0). The CLEC16A SNP rs6498169 that was 
identified here as genome-wide significant is in a different haplotype block (R2=0.2), suggesting that in a 
single gene different SNPs are involved to different autoimmune disorders. A third autoimmune disorder 
that has been associated with CLEC16A is autoimmune Addison’s disease.22 It remains to be determined 
to what extend the different genetic variants within the CLEC16A area contribute to the susceptibility for 
certain autoimmune disorders. 
Still little is known regarding the function of CLEC16A protein in humans. It is a member of 
the C-type lectin family, of which members have described to provide signals for a decision between 
tolerance and immunity. They can bind bacterial products as well as endogenous ligands, and their 
signal can counteract the signal of Toll-like receptors, therewith influencing T-helper cell function. We 
previously implied a role for C-type lectin receptors in MS pathogenesis, and discussed a link with 
infections.23 However, further research has to be undertaken to understand the exact function of the 
CLEC16A gene and subsequently how it could influence the susceptibility to MS.
Not surprisingly, many of the risk genes identified thus far are directly linked to adaptive 
immune functions, further stressing the autoimmune pathogenesis of the disease. IL2R and IL7R are 
receptors for the regulation of lymphocyte expansion and differentiation. CD58 and CLEC16A both share 
functional characteristics with the recently identified MS risk gene CD22620,24,25 that reached genome-
wide significance,20 by their involvement in cell-cell interaction, adhesion and signaling. 
So far KIF1B has been reported the only neuronally expressed gene with genome-wide 
significant association with MS.11 
It is of note that many by now validated and strongly suggested MS susceptibility loci are 
also associated with other autoimmune diseases such as TID and Graves’ disease. Although these genes 
may very well account for the clustering of MS and other autoimmune diseases in certain populations 
and within families, also here again the protective as well as risk alleles MHC class II area may exert the 
strongest effects. 
Some immunodulatory treatments can trigger autoimmune diseases such as Graves’ disease 
or idiopathic thrombocytopenic purpura (ITP) in MS patients.26,27 Genotyping of the overlapping 
autoimmune risk alleles24 may identify patients at risk for such autoimmune side effects. 
In conclusion, in this study genome-wide significant association of non-HLA risk genes with 
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susceptibility to MS is confirmed for CD58, CLEC16A, IL2R and IL7R. Several of the by now validated and 
strongly suggested risk genes are shared by different autoimmune diseases, including the risk genes 
for which we found genome-wide significance. A question that remains to be answered is if the SNPs 
in these are causative variants. Fine mapping studies will be needed to determine the functional 
contributions to the distinct autoimmune phenotypes.
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Abstract
The few loci associated with multiple sclerosis (MS) are all related to immune function. We report a GWA 
study identifying a new locus replicated in 2,679 cases and 3,125 controls. An rs10492972[C] variant 
located in the KIF1B gene was associated with MS with an odds ratio of 1.35 (P =2.5 x 10-10). KIF1B is a 
neuronally expressed gene plausibly implicated in the irreversible axonal loss characterizing MS in the 
long term.
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MS is a complex disease resulting from genetic and environmental factors. The genetic influence on MS 
susceptibility is substantial, as evidenced by the 20-fold increase in risk for siblings of individuals with 
MS. Part of the high recurrence risk is explained by the MHC class II locus.1 A recent GWA study2 done 
by the International Multiple Sclerosis Genetics Consortium (IMSGC) reported association of MS with 17 
SNPs in 14 loci. Although most loci were consistently associated, only variants in two genes, HLA-DRA 
and IL2RA, achieved genome-wide significance (P value <5 x 10-8). For a third gene, IL7R, convincing 
functional support was obtained. IL2RA and IL7R are both related to T-cell function and have also been 
linked to other autoimmune diseases.2,3 However, these genes lack specificity for the central nervous 
system (CNS) pathology seen in individuals with MS.      
 We conducted a GWA study in 45 MS cases and 195 controls from a young genetically isolated 
Dutch population4,5 using Affymetrix 250K Nsp array from GeneChip Human Mapping 500K Array 
Set (Supplementary Methods). We reasoned that the relative homogeneity of the sample would be 
advantageous. Association analysis did not reveal any SNP achieving genome-wide significance; the 
lowest P value observed was 10-6. However, we did detect a signal in the KIF1B locus (chromosome 
1p36.22) that was characterized by multiple associated SNPs (Figure 1). Although the significance for 
individual SNPs was modest for a GWA analysis (lowest P =0.0004 for rs10492972), the odds ratio (OR) 
for rs10492972[C] was 3.12 (95% CI =1.66–5.86) per allele, and 14 (52%) out of 27 SNPs in the 500-kb 
region surrounding rs10492972 showed association with P values < 0.05. There is extensive linkage 
disequilibrium (LD) in the KIF1B locus, and the boundaries of the major haplotype block, as estimated 
using HapMap CEU data (Figure 1), coincided well with the boundaries of association. When we included 
rs10492972 in a logistic regression analysis, no other SNPs remained significant (all P > 0.05), suggesting 
that association with the other 13 SNPs was most likely explained by LD with rs10492972. Strong LD 
is expected to occur around a causal variant, in particular when affected individuals are derived from 
a genetic isolate. As KIF1B is shown to encode a protein involved in axonal function, we followed up 
on rs10492972 in three replication sets of individuals with MS ascertained in outbred populations 
(Supplementary Methods): (i) a cohort from the Dutch general population (490 MS cases and 426 
controls), (ii) a cohort from the Swedish general population (826 MS cases and 997 controls) and (iii) the 
Canadian Collaborative Project on the Genetic Susceptibility to MS (CCPGSMS; 1,318 individuals with MS 
and their parents). In total, we studied 2,634 cases and 2,930 controls in the replication phase.  
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Figure 1 Association of MS with KIF1B region in a Dutch genetically isolated population. Blue, directly typed SNPs; 
gray, imputed SNPs. Linkage disequilibrium plot is constructed using the HapMap CEU data.
 In each replication cohort, significant association of MS with the rs10492972[C] allele was 
demonstrated, with ORs consistently ranging from 1.3 (Swedish cohort) to 1.42 (Dutch outbred cohort). 
In each cohort, the frequency of the C allele was very similar and close to 0.34 in cases and to 0.27 in 
contrsols (Table 1). A meta-analysis of the data resulted in a joint OR of 1.35 (95% CI =1.23-1.48), with 
a significant P value of 2.5 x 10-10. Analysis of genotypic model (Table 1) suggests that the effect of 
rs10492972[C] on the log(OR) scale is well approximated by the additive model. 
Table 1 Results from the individual studies and meta-analysis of association between rs10492972[C] (KIF1B region) 
and MS
Additive model Genotypic modela
Cohort No. 
cases
No. 
controls
     RAFa      RAFu      ORc P  ORCT PCT ORCC PCC
Dutch isolated 45 195 0.43 0.21 3.12 0.0004b 2.73 0.007 11.23 0.0001
Dutch outbred 490 426 0.34 0.27 1.42 0.0009 1.50 0.004 1.85 0.010
Swedish 826 997 0.34 0.29 1.30 0.0003 1.25 0.025 1.75 0.001
Canadac 1,318 1,507 0.34 0.27 1.31 0.0012 1.21 0.002 1.45 0.004
Pooled 2,679 3,125 0.34 0.27 1.34 2.5 x 10-10 1.27 1 x 10-6 1.67 4 x 10-8
RAFa, risk allele frequency in affected individuals; RAFu, risk allele frequency in unaffected individuals.
aOrs and P values are given for the comparison with the TT reference group. bCorrected using genomic control. cTrio design, TdT 
analysis.
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 Rs10492972 is located in intron 5 of the KIF1B gene. Although analysis of imputed data (Figure 
1) did not reveal any SNP more strongly associated with MS than the original rs10492972, we cannot claim 
that rs10492972 is the true causative variant. The question of whether rs10492972 itself, or an associated 
structural or regulatory polymorphism, is responsible for the association observed remains open. KIF1B 
has been linked to the inherited peripheral neuropathy Charcot-Marie-Tooth disease (CMT2A) in a single 
Japanese family.6 However, later studies have shown that mutations in MFN2 (mitofusin-2), which is located 
2 Mb from KIF1B, are responsible for most cases of CMT2A linked to this locus.7 In our study, SNPs in MFN2 and 
its surrounding area (± 100 Kb) did not show evidence for association to MS (all P > 0.01).   
 Given the strong evidence for an autoimmune origin of MS, it was not unexpected that 
the first MS genes discovered by the IMSGC GWA2 were related to T-cell function. There is, however, 
increasing evidence for neurodegenerative processes in MS pathology. Irreversible axonal loss is an 
important mechanism in the development of permanent neurological symptoms.8 Although primary 
demyelination may underlie early axonal loss, further progression of neurodegeneration occurs when the 
compensatory capacity of the CNS is exceeded and the threshold of axonal loss is reached.8 Mechanisms 
proposed for this loss of nerve fibers include mitochondrial dysfunction, reduced ATP production and 
altered axonal expression of sodium channels.9-11 KIF1B encodes a kinesin superfamily member believed 
to be responsible for axonal transport of mitochondria and synaptic vesicle precursors.12, 13 It has an 
ATPase binding domain and is enriched in motor neurons. Recently, dysregulation of ATPases and 
mitochondrial mislocalization have been shown to have a role in several neurodegenerative diseases.12 
KIF1B knockout mice clearly showed CNS abnormalities such as atrophy.6
 The discovery of KIF1B is based on what may be the smallest number of cases studied by a 
GWA study. Although the a priori power was low, even in a genetically isolated population, the ability to 
locate this gene is most likely due to the demonstrably extended LD around rs10492972 in the isolate.14 
Genome-wide significant replication of the findings in the series of MS cases from the general Dutch, 
Canadian and Swedish populations confirmed the association of s10492972 to MS. We have previously 
confirmed the role of EVI5,15 one of the putative 17 MS loci proposed by the IMSGC consortium.2 Notably, 
both EVI5 and the newly identified KIF1B showed higher ORs in our recently isolated population, as 
compared to the general population (P =0.03 and 0.01, respectively). For KIF1B, this is difficult to interpret, 
as ORs are often inflated in the gene discovery sets. However, the finding for EVI5, which is based on a 
confirmation study, suggests that founding effects and genetic drift may have led to an enrichment of 
genetic variants and their effects in the genetic isolate.
 Our study establishes a new genetic variant, rs10492972[C], that is associated with the risk of 
MS in the general population. This SNP is located in intron 5 of the KIF1B gene and may explain part of 
the progressive neurodegeneration seen in individuals with MS. Further functional studies are required 
to establish the exact role of the KIF1B gene region in the pathogenesis of MS. 
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SuPPLEMENTARY METHODS AND RESuLTS
Genetic variation in the KIF1B locus influences susceptibility to multiple 
sclerosis
Patients & genotyping
All patients fulfilled either Poser’s criteria for definite multiple sclerosis or McDonald’s criteria for multiple 
sclerosis. Each participating site has obtained ethical approval from the relevant institutional review 
board.
The Netherlands MS series. In the screening phase, we performed a GWA study on 45 MS patients from the 
Genetic Research in Isolated Populations (GRIP) program. As controls, we included 195 healthy individuals 
from the same area who were all distantly related. Details on ascertainment are given elsewhere.1 The 
250K Nsp array from the GeneChip Human Mapping 500K Array Set was applied to genotype with cohort 
genome-wide; BRLMM algorithm was used for genotype calling. Details are described elsewhere.2
For the replication cohort we recruited and ascertained MS patients as part of an ongoing 
nationwide study on genetic susceptibility in MS. At total of 494 MS patients were included, 374 sporadic 
MS patients and 120 cases from 120 multiplex MS families (i.e. families with two or more MS patients). 
Ten percent of the patients (n=51) had a clinically isolated syndrome at the time of enrollment. The 429 
healthy controls consisted of 29 unrelated spouses, together with 400 healthy blood donors.
Genotyping in the replication sample was carried out using the MassARRAY system 
Homogeneous MassExtend assay, following the protocol provided by Sequenom. PCR and extension 
primers were designed using the Assay Design 3.0 program (Sequenom). Briefly, 20 ng genomic DNA 
is PCR amplified using Titanium Taq DNA Polymerase (Clontech). PCR primers were used at 200 nM 
final concentrations for a PCR volume of 10 l. The PCR condition was 95°C for 15 min, followed by 
denaturing at 94°C for 20 sec, annealing at 56°C for 30 sec, extension at 72°C for 1 min for 45 cycles, and 
finally incubation at 72°C for 3 min. PCR products were first treated with shrimp alkaline phosphatase 
(Sequenom) for 20 min at 37°C to remove excess dNTPs. ThermoSequenase (Sequenom) was used 
for the base extension reactions. Analysis and scoring were performed using the program Typer 3.3 
(Sequenom).
Swedish case-control data set. In the Swedish study, 826 MS patients were collected at Karolinska University 
Hospital, Stockholm, Sweden. Further, 997 healthy blood donors from the Stockholm area served as 
controls. Genotypes for rs10492972 were assessed using a pre-designed TaqMan® SNP Genotyping 
Assay (Assay ID: C__30400488_20, Applied Biosystems). Primers were diluted four times compared to 
the manufacturer’s manual. Allelic discrimination was performed using the Applied Biosystems 7900HT
Fast Real-Time PCR equipment and the interpretation was done using the SDS 2.2.1 software (both from 
Applied Biosystems).
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Canadian Collaborative Project on the Genetic Susceptibility to MS (CCPGSMS). A total of 2,825 individuals 
from 300 parent-child trios and 456 multi-case nuclear families comprising affected children and their 
parents were typed as part of the CCPGSMS for which the methodology has been described.3,4 This 
includes 1,318 individuals with definite MS and 1,507 of their unaffected first-degree relatives. The 
Canadian families consisted of 456 multiplex MS families and 300 parent-child trios. All genotypes were 
generated blind to pedigree structure and disease status of the individual. Genotyping of SNPs was 
performed using the Sequenom MassEXTEND protocol (www.sequenom.com). Only conservative and 
moderate genotyping calls were accepted in this study. Samples having aggressive or low probability 
quality genotypes were reanalysed.
Statistical analysis
Genome-wide association analysis was performed using GenABEL package.5 Only SNPs having minor 
allele frequency of at least 1% and demonstrating call rate of >93% were included in the study.
We have studied relations between people included into a GWA scan performed in the Dutch 
genetically isolated population using the genomic kinship (IBD) data estimated as described by Amin 
et al.6 The 45 cases and 195 controls used in this study made a total of 28,680 pairs; of these 99.2% had 
genomic kinship of <0.0156 (1/26). Twenty-two pairs (0.08%) had genomic kinship between 0.13 and 
0.0625, indicating possible second-degree relations.
 Principal component analysis of the genomic kinship matrix7 has not revealed genetic outliers 
and has also shown that cases and controls are well genetically matched. This is not surprising given the 
nature of population and careful selection of cases and controls on the region of origin and ethnicity.
 It is known that even a small fraction of related people may cause inflation of the association 
test statistic when highly heritable traits are studied. We6 and others have shown that genomic control 
(GC) can be effectively used to correct for such inflation. Therefore all results reported in the manuscript 
use genomic control correction, as estimated using qtscore function of GenABEL package.5 GC λ was 
estimated as 1.37.
 The Armitage trend test was used to access the significance of association between the 
disease and genotypes (coded as 0, 1, or 2; additive model). All results reported for the GRIP use genomic 
control8 correction for possible inflation of the test statistics. Furthermore, EIGENSTRAT analysis7 with up 
to ten principal components was performed to ensure robustness of results against false-positives.
 In the analysis of GWA data, four SNPs reached genome-wide significant level with P <5 x 10-8. 
These SNPs exhibited very low risk allele frequency in controls (MAF<1%) and high frequency in cases 
(MAF>12%). Since array genotyping is susceptible to bias,9 we have re-genotyped these 4 SNPs together 
with an additional 18 “top” novel hits (score test corrected P-values ranging from 1.4 x 10-9 to 1.6 x 10-5) 
using Sequenom MassARRAY system. We further searched for extended regions showing evidence for 
association to the disease, which characterizes regions including disease genes.10 This method is particularly 
powerful in isolated populations.11 For this reason, the KIF1B rs10492972 (rank = 89) was also included in the 
Sequenome retyping.
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 These 23 SNPs were also genotyped in the Dutch outbred cohort (494 cases and 429 controls). 
After re-genotyping the four genome-wide significant hits were found to be false positives generated 
by genotyping error. The lowest P-value in our GWAS was 10-6. Despite that, the KIF1B rs10492972 
showed a high consistency (99.1%) between Affymetrix and Sequenom genotypes and, additionally, 
showed evidence for association (P =0.0008) with MS in the Dutch outbred cohort. Therefore this SNP 
was followed up in two other outbred cohorts (Swedish and Canadian samples).
In the Dutch genetically isolated population, the corrected P-value for the SNP rs10492972 was 
estimated as 0.0002 when using the score test and 0.0004 when using Wald test based on the corrected 
estimates obtained in the logistic regression analysis. As an extra quality check, we performed EIGENSTRAT 
analysis7 using up to 10 principal components. This analysis did not change our results concerning KIF1B; 
the P-value for rs10492972 ranged from 0.0001 (1 component) to 0.0003 (6 components). Imputations in 
the regions of interest were performed using MACH program12 with HapMap release 21 CEU population 
as reference. Only imputed SNPs showing the ratio of observed to the expected variance (r2) over 0.8 
were considered in analysis (Figure 1).
 In the three outbred populations, no genomic correction was performed because of absence 
of genome-wide data. However, the fact that the ORs obtained in Dutch and Swedish outbred cohorts 
were very similar to those obtained from the Canadian sample transmission-disequilibrium test analysis, 
makes it unlikely that these two series of patients, both derived from very homogeneous populations, 
were biased by population stratification and leaves no opportunity that KIF1B finding is a false-positive 
due to population stratification.
 In the Dutch outbred population and Swedish cohorts, odds ratios and P-values were estimated 
using logistic regression as implemented in glm function of R v. 2.6.2. In the Canadian Collaborative 
Project on the Genetic Susceptibility to MS cohort, affected offspring analysis was performed with TDT 
as implemented in PLINK package.13 The calculations are done by permuting parent alleles while fixing 
the IBD status of sibs within a family. The odds ratio was calculated as described in Kazeem and Farrall.14 
Meta-analysis was done using inverse variance pooling of log-odds ratios.
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Multiple sclerosis (MS) is a complex disease and is thought to be the result of many environmental and 
genetic risk factors as well as a complex network of gene-gene and gene-environment interactions. For 
over 30 years the major histocompatibility complex (MHC) has been the only genetic association with 
susceptibility to MS.1 The attributable risk of other risk alleles is probably very small. Detecting these is 
very difficult, requiring large populations. However, pooling studies might result in more heterogeneous 
populations, making it more difficult to detect risk genes. 
In this chapter I will discuss our main findings and how our findings fit into current knowledge 
of MS genetics and pathogenesis. Finally, I will discuss the future prospectives in MS genetics and the 
consequences for the understanding of the pathogenesis of MS and the development of new therapies 
for MS. 
Gene discovery
General principles
Family based versus population based genetic studies
There are two principal approaches to identify disease genes: linkage and association studies. In 
linkage studies families with a number of affected persons are required to investigate whether discrete 
chromosomal segments deviate from independent segregation and co-segregate (i.e. link) with the 
disease. Linkage studies will identify genes that are very rare but do have major effects. 
In association studies the frequency of alleles at a polymorphic site in well-matched groups 
of affected and unaffected individuals are compared. Association studies have greater statistical power 
than linkage studies to detect common genetic variants that confer a modest risk of disease,2 but are 
potentially important for defining new insights in disease pathogenesis. A disadvantage is that rare 
variants are generally not identified with association studies, whereas complex diseases are most likely 
to be caused by a complex interaction of both common variants with low penetrance and rare variants 
with high penetrance.3 
Initially, most association studies have focussed on candidate genes. The main disadvantage 
of this approach is that it does require a hypothesis, based on the known function of the gene. Genome-
wide association studies (GWAS), in which a sufficiently large number of well-spaced single nucleotide 
polymorphisms (SNPs) provide almost complete genomic coverage, do not require a previous 
hypothesis. GWAS are based on Chip technology, which allows the efficient genotyping of several 
hundred thousand SNPs throughout the genome simultaneously. However, given the many tests 
performed simultaneously, one has to make very stringent corrections for multiple testing. The level for 
genome-wide significance has been set at P <5 x 10-8, representing Bonferroni correction for the number 
of blocks present in the human genome.4 
Genetic association for complex diseases may be probed either with case-control studies 
of unrelated people or with family-based design. Both designs have advantages and disadvantages. 
The advantage of studies with unrelated cases and controls is that sufficiently large study populations 
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can readily be assembled without the need to enrol also family members of the recruited participants. 
However, a disadvantage of this approach is that confounding due to unaccounted population 
admixture remains a possible threat to the validity of obtained results.5-7 On the other hand, family 
based study designs have the advantage that there is a common genetic background among the family 
members. Thus, the problem of population stratification is bypassed. Moreover, families tend to be more 
homogeneous regarding exposure to environmental factors possibly associated to the disease etiology. 
Genetic studies in isolated populations
The selection of a population is crucial for genetic research. In order to reduce the problem of genetic 
heterogeneity, population isolates can be used in attempts to map genes underlying complex 
diseases.8-12 Individuals from genetically isolated populations show significantly less genetic diversity 
compared with individuals from outbred populations.13,14 The reduced genetic diversity is the result of 
a small number of founders, the occurrence of population bottlenecks and genetic drift. Population 
bottlenecks are the result of a sudden decrease in size, which is often seen in isolated populations in the 
form of famine, infectious disease epidemics and war. These population bottlenecks are followed by the 
survival and expansion of a small random sample of the original population. Predisposing genes for a 
disease are thought to be the same in patients from an isolate due to a restricted number of ancestor 
mutations.
In addition to the increased genetic homogeneity, isolates create a powerful setting to study 
the genetics of complex diseases through the usually available accurate genealogical records, which 
allows for the analysis of extended pedigrees. 
In population isolates, particularly in those founded recently, fewer meiotic events will have 
occurred since a founder introduced a mutation in the gene pool. As a consequence it will be less 
likely that an ancestral haplotype has been disrupted by a recombination event, increasing the extent 
of linkage disequilibrium (LD) and thus the size of the shared haplotype. Hence, in comparison with 
outbred populations, such isolates may require fewer markers for GWAS or may achieve better genome-
wide coverage with equivalent numbers of markers.9,15 The disadvantage of GWAS carried out in genetic 
isolates is that the strong LD that initially helped to identify the disease locus may in the end hamper 
efforts to distinguish the biologically relevant variants from insignificant polymorphisms in complete LD 
with them. 
Gene identification in multiple sclerosis
Although familial aggregation of MS has been recognized for long,16,17 so far the mode of inheritance 
remains unclear. 
Some studies suggested that a single genetic abnormality might be sufficiently severe to result 
in a form of inheritance following a Mendelian pattern. An autosomal dominant mode of inheritance of 
MS with reduced penetrance has been proposed for one family.18 Autosomal recessive inheritance has 
been suggested in other studies19,20 but either mode of inheritance remained unproven. In the majority 
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of patients, MS is probably the outcome of the additive effects of multiple genes with complex gene-
gene and gene-environment interactions.
Family-based studies 
Linkage screens with different levels of resolution and genome coverage have been completed in more 
than 30 data sets of familial MS cases.21 Multiple chromosomal regions with potential involvement in MS 
susceptibility were suggested in each of these studies, consistent with the long-held view that MS is the 
result of many different genetic risk variants. However, no other region than the HLA-class II locus within 
the MHC region on chromosome 6p21.3 has exceeded the threshold for formal statistical significance. 
To assess the full potential of the linkage approach in MS, the International Multiple Sclerosis Genetics 
Consortium (IMSGC) reported in 2005 the results of a linkage screen in 730 multi-case MS families, using 
more than 4,500 SNPs. The higher peak LOD score of 11.7 in the HLA locus illustrates the substantial 
greater power of this high density screen compared with earlier efforts. Strikingly no other locus reached 
genome-wide significance in this screen.22 However, there were non-MHC peaks of linkage observed, 
which failed to reach genome-wide statistical significance. These peaks do provide a useful guidance for 
the size of effects likely to be attributable to non-MHC susceptibility loci. It was calculated that common 
non-MHC risk alleles are highly unlikely to increase MS risk by more than a factor of 2.0.2,22-24 
Genome-wide linkage screens were also done in a cohort of forty families in which four 
or more individuals were affected with MS25 and in a single pedigree with a high prevalence of MS.27 
These screens also showed no evidence of linkage outside the MHC region. However, the size effect of 
the MHC appeared to be greater in families with many affected individuals.26, 27 It was speculated that 
non-MHC susceptibility loci would have larger effects in multiplex families. Therefore 13 candidate non-
MHC gene loci, identified as susceptibility loci for MS in an association screen performed by the IMSGC 
(described later in this discussion),28 were tested for association in the multiplex families. The aggregate 
results demonstrate that the MS families have risk genes similar to that of the general MS population. 
However, the multiplex families showed higher risk allele frequencies than in sporadic cases, and they 
also exhibited a significant aggregation of susceptibility loci. Both factors seem to result in the increased 
susceptibility of MS within these families.29
Studies in isolated populations
Familial clustering of MS has been found in a northern Swedish rural district,30 the county of Värmland 
in mid Sweden,31 in an isolated population of Sardinia,32 Southern Ostrobothnia in Finland 33 and in the 
Dutch genetic isolate we studied.34
As described in chapter 2, we identified MS patients in a genetically isolated population in 
the southwest of the Netherlands. We studied this population as part of the Genetic Research in Isolated 
Populations (GRIP) program. Extensive genealogic data were available for this population. We were able 
to construct a pedigree in which 24 of the 48 MS patients from the genetically isolated population could 
be linked to a common ancestor in 14 generations. Using the genealogical data we also found that the 
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MS patients were significantly more often related to each other and significantly more often inbred 
(higher probability that two alleles in one patient are identical by descent) than a non-MS control group 
derived from the same isolate.34  
Studies in Southern Ostrobothnia in Finland demonstrate the power of population isolates 
in the identification of rare disease alleles. Southern Ostrobothnia is a genetic isolate in Finland with 
an exceptionally high prevalence and familial occurrence of MS.33 In Finnish MS families enriched with 
cases from this isolate, linkage of MS to chromosome 5p had been detected.8,35 The IL7R gene is located 
in the chromosome 5p region and this gene has been linked to MS in several population studies, as I will 
discuss further on. The 5p locus was studied further in the Finnish isolate and monitored for haplotype 
sharing. This analysis revealed only modest association at IL7R, whereas most significant association was 
found with one haplotype covering the C7-FLJ40243 locus, 5.1 Mb centromeric from IL7R. The identified 
risk haplotype (~4% in the general European population) is relatively rare, but it has obviously become 
enriched in the southern Ostrobothnian high-risk MS region (12% of cases).12 It contains complement 
component 7 (C7), an important factor for the innate immunity. 
Interestingly, the risk genes for MS we confirmed (EVI5, chapter 4) and identified (KIF1B, 
chapter 5) in the GRIP population demonstrated higher odds ratios (OR) in our isolate compared to the 
general population, which is most probably due to the enrichment of genetic variants in the isolate as a 
consequence of founder effect and genetic drift.
Population studies 
Candidate gene studies
Population-based association studies of candidate polymorphic genes, in which the frequencies 
of marker alleles in groups of patients and healthy controls are compared, have only been modestly 
successful in identifying disease-causing genes in MS, with the notable exception of the MHC locus. 
This is in part because of the difficulty in selecting from the many candidate genes without an unifying 
model of disease pathogenesis.
Genome-wide association and replication studies  
Recently, the IMSGC performed a GWAS, using DNA microarray technology. In the screening phase 
>300,000 SNPs were tested in 931 trio families (half from the US and half from the UK). As would be 
predicted, the limited power provided by 931 trio families meant that no unequivocal associations were 
identified in the screening phase, outside the expected signals from the MHC region. For the replication 
phase 110 SNPs were selected on the basis of statistical significance and proximity to previously 
identified loci associated with susceptibility to autoimmune diseases. Finally, a joint analysis of data from 
12,360 subjects was performed. The results revealed the existence of 16 non-MHC susceptibility SNPs 
in 13 gene loci of modest effect. However, only the non-MHC SNP in the IL2RA gene achieved genome-
wide significant association with susceptibility to MS (P =3 x 10-8).28
Other powerful GWAS and studies aiming to replicate genes identified in GWAS, including 
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ours as described in chapter 4 and 5, showed genome-wide significant association with susceptibility 
for MS for several variants: HLA, IL7R,38 IL2RA, KIF1B, CLEC16A (KIAA0350),36-38 CD226 (DNAX accessory 
molecule 1, [DNAM-1]),36 CD58,38 CD6, 39 IRF8 (ICSBP1),39 TNFRSF1A,39 a locus on chromosome 12 most 
probably relating to the gene CYP27B,40 TYK2,41-43 STAT3,44 KIF21B45,46 and TMEM39A.45 These associated 
variants, except TYK2 (mean allele frequency (MAF) <0,05) are common, have small odds ratios and 
explain only a fraction of the genetic risk.
In chapter 4 we describe results of  our studies, aiming to analyse the by the IMSGC identified 
MS risk genes.28 In chapter 4.1 we confirmed EVI5 as a risk gene for MS in the Dutch genetically isolated 
population, despite the low numbers to verify the ORs of the risk genes identified by the IMSGC. 
Successively, we also confirmed EVI5 as a risk gene for MS in an independent Canadian population, 
which strengthens the evidence that EVI5 is associated with MS risk. In both populations the association 
was marginally significant (P =0.01 and 0.04 respectively). For the other 14 non-MHC SNPs described to 
be associated with MS risk by the IMSGC, we found no statistical evidence for an association. This does 
not exclude an effect of these SNPs as the probability of finding false-negative findings is high in our 
study, because of the low numbers. EVI5 is a common site of retroviral integration and has been linked 
to lymphomagenesis.  Further studies will have to elucidate to what extend it could influence T-cell 
function and whether it could be related to retroviral elements associated with MS.47 
The results of our study as described in chapter 4.2 and our GWAS as described in chapter 5 
will be discussed later.
Do identified risk variants result in a better understanding of MS 
pathogenesis?
It remains important to recognize that identified disease associated genetic variants not necessarily 
cause the disease, but can also be markers of it. Most of the non-MHC loci are thought to confer disease 
susceptibility because they are the dominant candidate genes in a region of LD, in which a SNP or set 
of SNPs have been associated with disease. Many genes and associated variants are inherited together 
owing to LD in the genome. The current tools of human genetics cannot easily distinguish between a 
marker variant and a causal variant if the LD between them is either strong or absolute. The identification 
of the disease-causing variant will ultimately depend on functional studies.
Function of identified risk variants
The function of not all the currently identified risk variants is exactly known. Interestingly, most of the risk 
variants with known function have primarily immunologic functions. 
 I will describe what is known about the function of the different identified risk variants for which 
a genome-wide significant association with MS has been shown. Furthermore, I will give an overview of 
the level of evidence for association of each risk variant with MS (which can also be only a marker for the 
real disease causing genes as described above), dividing the risk variants in three groups: those with very 
high evidence, those with high evidence and those with modest evidence for an association with MS. 
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Very high evidence for an association
MHC class II 
MHC class II molecules are highly polymorphic cell-surface glycoproteins that present antigen to CD4+ 
T helper cells and are integral to successful maintenance of self-tolerance by the immune system and 
the adaptive immune response to invading pathogens.48 Each HLA-DRB1 allele forms, by the presence of 
defined amino acid anchors, a number of specific pockets comprising a peptide-binding groove.49 The 
binding affinities for disease-related peptides may thus be different for different HLA-DRB1 molecules 
as determined by their protein sequence. Subsequently this may influence composition of T-cell 
repertoires and ultimately result in HLA-DRB1 alleles having varying effects on disease risk.50 However, 
protein sequence analysis failed to provide unequivocal support for this hypothesis. Perhaps  antigen 
presentation is not the sole mechanism of the MHC association in MS.51 
Association of MS with the DR15 haplotype from the MHC on chromosome 6p21, has been 
established for more than 30 years52 and is confirmed in nearly every population studied.53   
IL7R
IL7R encodes for the receptor for interleukin-7, which is expressed on T and B-lymphocytes. The signal 
transduced by this receptor is crucial for lymphocyte survival and immune homeostasis. Initial functional 
data suggest a change in the rate of membrane-bound and soluble forms of the IL7RA for individuals 
carrying the risk allele.54 It is still not known how this change could influence the function of the IL7RA.
Results of the first GWAS from the IMSGC showed a highly significant association  (P =3 x 10-7) 
of MS with a SNP in the IL7R gene,28 although not reaching genome-wide significance. Strikingly, the 
same SNP was almost simultaneously identified and replicated in a different study (in total 2,853 cases, 
3,204 unrelated controls and parents of 1,338 MS patients, combined P-value =2.9 x 10-7) which used 
genomic convergence (multifactorial, multistep approach that combines gene expression with genomic 
linkage analysis) to select candidate genes that were differentially expressed between MS patients and 
controls.54 Since then the association of MS with IL7R has been confirmed in several populations.38, 55-59 
In two studies,38,58 including our meta-analysis (described in chapter 4.2) a genome-wide significant 
association with MS was found. 
Apart from the HLA region to date IL7R clearly represents the gene with most evidence for 
an association with MS susceptibility. However, a recent study of African Americans did not provide 
evidence for an association in that population.60 
IL2RA 
IL2RA encodes for the alpha chain of the interleukin-2 receptor (IL2R, also known as CD25).  The 
involvement of the IL2R chain in the pathogenesis of MS might be related to the important role that 
the IL2–IL2R pathway plays in adaptive immune functions. For MS patients carrying the IL2RA variant a 
change in the rate of membrane-bound and soluble forms of the IL2R was found.61,62
In the GWAS of the IMSGC, besides the HLA region, only one SNP in the IL2RA gene achieved 
genome-wide significant association with MS (P =3 x 10-8).28 Yet, several groups have reported an 
association of SNPs within IL2RA with MS,37,38,56,59,63,64 although the associated variations varied across 
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populations. In our meta-analysis (chapter 4.2), we also showed a genome-wide significant association 
of IL2RA with susceptibility for MS (P =7 x 10-11).38 It has not yet been possible to pin-point the exact 
causative variation(s) in this gene or to detect functional relevance. In a large Australian population a 
fine-mapping study suggested allelic heterogeneity at the IL2RA locus and the existence of at least two 
independent susceptibility alleles.63
CD58
CD58 encodes a ligand for the T-cell specific CD2 membrane molecule, an adhesion molecule that 
transduces important signals for T-cell proliferation and differentiation. The CD58 genetic variant that 
is most strongly associated with MS has a protective effect on MS development. Functional analyses 
revealed that this variant was associated with increased mRNA expression in cell lines as well as in 
mononuclear cells from MS patients. Furthermore, CD58 mRNA levels are elevated in MS subjects during 
clinical remission, again supporting the hypothesis of a protective effect.65
In the first GWAS of the IMSGC, evidence was already found for an association of CD58 
with susceptibility for MS (P =2 x 10-5). The Australian and New Zealand Multiple Sclerosis Genetics 
Consortium showed a genome-wide significant association of CD58 with MS in the combined analysis of 
their GWAS and their replication study (in total 3,874 cases and 5,723 controls, P combined=10 x 10-8).40 
Furthermore a meta-analysis of GWAS (2,624 MS cases and 7,220 controls) and subsequent replication 
in an independent set of 2,215 MS patients and 2,116 controls from the United States (US) and United 
Kingdom (UK) showed a genome-wide significant association (P =3 x 10-10)39, which is in line with our 
meta-analysis (P =4 x 10-9)38 (chapter 4.2).
CLEC16A
For the CLEC16A protein still little is known regarding its function in humans. However, it is very 
likely that it does have a function in immune function. It is a member of the C-type lectin receptor family, 
of which members have described to provide signals for a decision between tolerance and immunity. 
They can bind bacterial products as well as endogenous ligands and their signal can counteract the 
signal of Toll-like receptors, therewith influencing T-helper cell function. Our group previously implied a 
role for C-type lectin receptors in MS pathogenesis, and discussed a link with infections.66 
In the GWAS performed by the IMSGC, a SNP in intron 22 of the CLEC16A gene showed 
evidence for an association with MS (P =4 x 10-6).28 In the recently published meta-analysis and replication 
study in MS patients from the UK and the US, the SNP rs11865121 in the CLEC16A gene was found to 
be associated with susceptibility to MS (P =2 x 10-7) in the joint analysis.39 In our meta-analysis (chapter 
4.2), we showed genome-wide significant association for the same SNP that showed evidence for 
association with MS in the GWAS performed by the IMSGC (P =3 x 10-12).28,38 In the Sardinian population 
an association with MS was revealed (1,498 MS cases and 1,706 matched controls) of a SNP in intron 
19 (P =7 x 10-5)67 and in a large Caucasian replication cohort (2,369 trio families, 5,737 cases and 10,296 
unrelated controls) of another SNP in intron 19 (P =2 x 10-16).36 Both SNPs have already been associated 
with Type 1 diabetes68,69 and are in perfect LD with each other (r2=1). The CLEC16A SNP in intron 22, that 
was identified in our meta-analysis to be genome-wide significantly associated with MS, is in a different 
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haplotype block (R2=0.2). This suggests that in a single gene different SNPs are involved in different auto-
immune disorders.
High evidence for an association
CD226 
CD226, expressed on natural killer cells, T cells, monocytes and subsets of B cells and platelets, is a 
transmembrane receptor of the immunoglobulin receptor family. It is implicated in T cell and NK cell 
mediated cytotoxicity and platelet activation. CD226 recognizes on most cell types, including neurons, 
endothelial cells and fibroblast, expressed poliovirus receptor and nectin-2.70 Interaction of CD226 
with poliovirus receptor on endothelial cells is involved in endothelial transmigration of leukocytes.71 
In experimental autoimmune encephalomyelitis (EAE), a rodent model for MS, anti-CD226 treatment 
results in reduced severity and delayed onset of the disease. This could be the result of altered T-cell 
activation, altered monocyte extravasation or altered natural killer cell responsiveness towards target 
cells.72 
An association with a coding SNP in the CD226 gene (Gly307Ser) was first reported for Type 1 
diabetes.69 Subsequent studies also showed an association of this gene with susceptibility for MS.36,73-75 
In the study by the IMSGC (2,369 trio families, 5,737 cases and 10,296 unrelated controls) a genome-wide 
significant association was found (P =5 x 10-8).36 
CD6
CD6 is a lymphocyte receptor that belongs to the scavenger receptor cysteine-rich superfamily. Its 
expression has also been reported in certain regions of the brain. CD6 contributes to either positive or 
negative modulation of the activation and differentiation signals for lymphocytes.87,88 
A genome-wide significant association of CD6 with MS was identified by pooling together 
data from three separate GWAS exploring susceptibility alleles for MS (total of 2,624 cases and 7,220 
controls) and replication in an independent US/UK cohort (2,215 cases and 2,116 controls, combined 
P =4 x 10-09).39 In one other recent replication study in Spanish MS patients  (2,515 cases and 2,942 
controls) an association of CD6 with MS was also identified (P =0.004).89
TNFRSF1A
TNFRSF1A encodes the p55 receptor for tumor necrosis factor alpha (TNF-α). Functional studies in human 
suggest that dysregulation of the TNF-α pathway has a role in the onset of MS. Diminished TNF-α activity 
seems to be associated with onset of CNS inflammatory lesions in clinical studies.90
The meta-analysis and replication study from de Jager et al.39 showed (besides CD6) a genome-
wide significant association of TNFRSF1A with susceptibility for MS (combined P =2 x 10-11). In the Spanish 
replication study89 a significant association of MS with TNFRSF1A was also identified (P =0.001). In both 
studies evidence was found for the existence of two independent risk effects at this locus.
TYK2 
TYK2 is a proximal tyrosine kinase in the STAT signalling pathway that is important for signalling by type 
I interferons and induction of Th1 cell differentiation upon antigen stimulation of dendritic cells.91 The 
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protective effect of the rare variant (MAF=0.04) in the TYK2 gene is predicted to give a less active variant 
of TYK2, which could lead to a shift to a protective Th2 response, and/or reduced Th1 or Th17 activation 
in MS.91
Alleles with a MAF below 0.05 are seldom included in GWAS because of the difficulties in 
detecting moderate genetic effects at this frequency level.7 In a combined analysis of results of a GWAS 
using non-synonymous coding SNPs (ns-SNPs)  for typing patients with autoimmune inflammatory 
thyroiditis, ankylosing spondylitis and MS, a rare variant of the TYK2 gene was identified as a possible 
susceptibility factor for MS.41 By adding  4,234 MS patients and 2,983 controls and 2,053 trio families to 
the analysis substantial evidence was found for an association of TYK2 with MS (combined P =3 x 10-06).42 
Because of the low frequency of the allele a genome-wide significant association of this gene with MS is 
very hard to establish. Therefore, an additional independent set of 5,429 MS patients and 6,167 controls 
was genotyped. By combining the data from all the three studies (10,642 cases, 10,620 controls and 
2,110 MS trios) a convincing level of genome-wide significance was reached (P =5 x 10-09).43 
KIF21B
KIF21B is a kinesin-like protein involved in axonal transport.92 KIF21B is expressed in a variety of immune 
cells. Although KIF21B has not been functionally associated with neurodegeneration or inflammation, 
given the nature and role of its protein in neurons, there is a plausible biological role for this gene in MS. 
In a follow-up study of the IMSGC genome-wide significant association of KIF21B with 
susceptibility for MS was found. In this study, approximately 30,000 SNPs were genotyped, that 
demonstrated mild-to-moderate levels of significance (P ≤0.10) in their initial GWAS,28 in an independent 
set of 1,343 MS cases and 1,379 controls. Several of the most significant findings were replicated in 
another independent data set of 2,164 MS cases and 2,016 controls. In a combined analysis, using data 
from the original screen (in total 931 trios, 3,507 cases and 8,024 controls) a combined P-value for KIF21B 
of 7 x 10-10 was found.45 Furthermore, in a recent Belgian study (791 cases 1,098 controls) an association 
of this gene with MS was found (P =0.01).46
Modest evidence for an association
KIF1B 
KIF1B encodes a kinesin superfamily member believed to be responsible for axonal transport of 
mitochondria and synaptic vesicle precursors.76,77 It has an ATP-ase binding domain and is enriched 
in motor neurons. Recently, dysregulation of ATP-ases and mitochondrial mislocalization has been 
shown to play a role in several neurodegenerative diseases.76 There is now increasing evidence that 
neurodegenerative processes, besides immunologic processes, are important in MS pathology. 
Irreversible axonal loss is an important mechanism in the development of permanent neurological 
symptoms.78,79 Though primary demyelination may underlie early axonal loss, further progression of 
neurodegeneration occurs when the compensatory capacity of the CNS is exceeded and the threshold 
of axonal loss is reached.78 Mechanisms proposed for this loss of nerve fibers include mitochondrial 
dysfunction, reduced ATP production and altered expression of sodium channels.80-82 KIF1B knockout 
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mice have CNS abnormalities such as atrophy.83
We conducted a GWAS in 45 MS patients and 195 controls from the GRIP population and 
described the results in chapter 5. In the screening phase no SNP revealed genome-wide significant 
association with MS. However, we did detect a signal in the KIF1B locus, which was characterized by 
multiple associated SNPs. After multivariate logistic regression analysis, only SNP rs10492972 remained 
significantly, although not genome-wide significantly, associated with MS. We replicated that SNP in 
three replication sets of MS patients: (1) a cohort from the Dutch general population, (2) a cohort from 
the Swedish general population and (3) trio families from the Canadian Collaborative Project on the 
Genetic Susceptibility to MS. We studied 2,679 patients and 3,125 controls in the replication phase. A 
meta-analysis of the replication results of the four independent populations resulted in genome-wide 
significant association of the rs10492972[C] SNP with MS (P =3 x 10-10). The a priori power to detect KIF1B 
was low, even in a genetically isolated population, regarding the small numbers of patients used for the 
GWAS. The ability to locate this gene is most probably due to the extended LD around the KIF1B SNP 
rs10492972 in the isolate.84 
However, in another study (by the IMSGC) this association of KIF1B with MS could not be 
replicated.85 In this study the rs10492972[C] variant of the KIF1B gene was genotyped in eight case-
control and three trio family collections (in total 22,854 individuals; 8,391 cases, 8,052 unrelated controls 
and 2,137 trio families). None of these populations showed any evidence of statistically significant 
association (Figure 1). In an Italian cohort rs10492972 has been genotyped in an outbred sample of 222 
primary progressive and progressive relapsing MS patients and 221 healthy controls of unique northern 
Italian origin. Carrying the rs10492972[C] variant had no effect on risk of disease or rate of disability 
progression.85
Case-control
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Figure 1 Odds ratio for the rs10492972[C] allele. The area of the symbol is proportional to the number of cases 
included in the respective analysis. The error bars indicate the 95% CI.  Data derived from Booth et al.85
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Although the association found between the KIF1B gene and MS has not been replicated, there 
is certainly not a lack of biological plausibility for an association of KIF1B and MS, given the increasingly 
recognized role of kinesins in neurological disease and the recent report on KIF1B and myelination.86 
As described another recent study from the IMSGC demonstrated quite strong evidence for 
an association of MS with KIF21B,45 a molecule sharing properties with KIF1B. A recent Australian-New 
Zealand screen found marginal association with an area around the KIF1A gene.40 Furthermore, more 
evidence that there does indeed exist a real association of KIF1B with MS comes from an unpublished 
study in an independent group of Canadian multiplex families (Ebers), in which an association of MS 
with rs10492972[C] was shown. 
We were surprised that our findings could not be replicated by the study of the IMSGC. There 
might be several explanations for this. A striking difference between the Italian study and the study done 
by the IMSGC versus our studies is the difference of allele frequencies in controls of rs10492972[C] (0.27 
in our studies versus 0.33 in the Italian study and 0.34 in the IMSGC consortium). Especially the controls 
from the genetic isolate in our population appear to have a low allele frequency, which may suggest that 
our control group was biased in some way. This may be attributed to founder effects, random effects that 
may occur in some isolates. Confounding due to population stratification is not a very likely explanation 
as it should have occurred in the four different populations that we analysed.  Furthermore, in our paper 
we used EIGENSTRAT analysis to adjust for this type of confounding and this type of confounding cannot 
affect the analysis of the multiplex MS families from Canada and the UK. 
Genotyping errors, which are often revealed as deviations from Hardy-Weinberg Equilibrium 
(HWE), could also be an explanation for the different study results. Genotype- and-allele frequencies are 
not in HWE for the UK cohort (P =0.04) and are borderline for the Italian cohort (P =0.08) of the IMSGC 
consortium. This could play a role in terms of the genotype distributions seen in cases and controls in 
the various cohorts of the IMSGC. 
Further, the different results could be the consequence of prevalence-incidence bias. A gene 
that is associated with survival after onset of the disease may result in a wide range of odds ratios in 
different studies, because of subtle differences in inclusion procedures. The Dutch population cohort 
was ascertained relatively early in the disease phase and a borderline significant association between 
KIF1B and age at diagnosis (P =0.09) was seen with age at diagnosis being 2.8 years later in patients with 
the KIF1B CC genotype. Adjusting for these age differences, a nominal significant association (P =0.04) 
still remained between KIF1B and the time between age at diagnosis and age at study inclusion, the 
KIF1BCC genotype being associated to a shorter period between diagnosis and study inclusion.    
The differences in allele frequencies in controls across populations of our study versus the 
IMSGC, the deviations from HWE seen in controls from the IMSGC and the possibility of incidence-
prevalence bias together, calls for further studies. Finally, deep sequencing of KIF1B may also help in 
resolving the issue.
IRF8
IRF8 is a member of the interferon regulatory factor (IRF) family, which is specifically expressed in immune 
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cells. The IRF8 locus contains an important transcription factor involved in responses to type I interferons 
(IFNα and β). Upregulation of interferon responses has been noted in peripheral blood of a subset of 
untreated MS patients.93,94 However, the role of interferons in the onset of MS is still unclear. Results of 
a recently performed expression study show that the susceptibility allele near IRF8 is associated with 
higher mRNA expression of interferon-response pathway genes in subjects with MS.39
A genome-wide significant association of IRF8 with susceptibility for MS was identified in the 
recently published meta-analysis (combined P =4 x 10-09).39 So far, only one replication study for IRF8 has 
been performed. In this study no association was found, which could also be due to lack of power (1,271 
cases and 1,525 controls).89
STAT3 
STAT3 encodes a transcription factor that is involved in multiple pathways and functions, including 
the Jak-STAT pathway, neuron axonal guidance, apoptosis, activation of immune responses and Th17 
cell differentiation.95 Mouse studies have shown that the targeted deletion of STAT3 in CD4+ T-cells 
prevents the development of experimental autoimmune encephalomyelitis.96 Moreover, increased 
phosphorylated STAT3 was reported in T cells of patients evolving from a clinically isolated syndrome to 
defined MS and in relapsing patients.97 
Evidence for an association of STAT3 with MS came from a GWAS, conducted in 68 distantly 
related MS patients and 136 controls from the high-risk isolated population of Southern Ostrobothnia in 
Finland. The loci with the lowest P-values (all < 10 x 10-04) were replicated in 711 MS patients and 1,029 
controls from Finland (83 MS patients and 365 controls were from the isolate in Finland). Subsequently, 
the top two SNPs were validated in 3,859 MS patients and 9,110 controls from more heterogeneous 
populations. In the combined analysis a genome-wide significant association of a common variant in 
STAT3 with MS was identified (combined P =3 x 10-10). This finding demonstrates the power of using a 
genetic isolate to complement large-scale GWAS in identifying common genes and not only in identifying 
rare high-impact alleles.44 However, in a replication study in Spanish MS patients no association of STAT3 
with MS was detected (1,540 cases and 1,720 controls).98
TMEM39A
Almost nothing is known about TMEM39A (mRNA-transmembrane protein 39A) and what biological role 
it might play with regard to MS susceptibility.
In the follow-up study of the IMSGC, TMEM39A was found to be genome-wide significantly 
associated with MS (combined P =3 x 10-08).45 Further studies have to be performed to strengthen the 
evidence for an association of this gene with MS.
CYP27B1 
CYP27B1 encodes the enzyme 25-hydroxyvitamin D-1 alpha hydroxylase, which hydroxylates 
25-hydroxyvitamin D into the bioactive form (1,25-dihydroxyvitamin D (1,25(OH)2D). This bioactive form 
regulates through the vitamin D receptor (VDR) the calcium metabolism. It also has important immune 
functions modulating innate as well as adaptive immunity and tolerance99 and B-cell homeostasis.100 
Furthermore it can direct activated T cells toward a T helper type 2 anti-inflammatory phenotype and 
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induce dendritic cells with tolerogenic properties.101 Epidemiological data suggest a link between 
vitamin D deficiency and increased incidence of MS and other autoimmune diseases.102-104
The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) performed 
a GWAS in 1,618 MS patients and 3,413 controls. Replication was performed in an independent set of 
2,256 cases and 2,310 controls. Two SNPs at chromosome 12 were associated at the genome-wide level 
in the combined cohort (P =5 x 10-11 and P =3 x 10-10). The strongest candidate gene given available 
genetic, immunological and epidemiological evidence was considered to be CYP27B1.40 
Systems biology
Many more markers tested in GWAS have shown association with MS, although not genome-wide 
significant. Because of the large multiple testing involved in these studies, very few exceed the genome-
wide significant threshold and those that do not are generally neglected. In many cases where loci with 
small but measurable genetic effects are involved, it is likely that, accepting the null hypothesis of no 
association, these loci represent false negatives. It is possible that meaningful combinations of genes, 
that showed only modest evidence of association in GWAS, can be identified if they belong to the same 
biological pathway or mechanism. 
In systems biology an integrative approach is used of available molecular, physiological, 
clinical, genetic, gene expression, proteomic and/ or biological information with the ultimate goal to 
identify pathways involved in the pathogenesis of diseases. Thereby real-world systems are represented 
as networks that interconnect different entities. In this way certain properties can emerge that cannot 
be derived from the individual analysis of each of their components.
Baranzini and colleagues have recently put current information on modest genetic effects 
in MS into a model linked to a human protein network. The aim of their study was to identify sub-
networks containing a higher proportion of genes associated with MS than expected by chance. Indeed 
interesting sub-networks of genes from several immunologic pathways involved in MS susceptibility 
were identified. Part of them were already known, but also novel neural pathways were uncovered.105 
MS and other autoimmune diseases
Intriguing is the fact that most of the above identified immune related SNPs that showed genome-wide 
significant association with MS, have overlapping associations with autoimmune conditions such as 
rheumatoid arthritis, inflammatory bowel disease, SLE, Type 1 diabetes and thyroid autoimmunity (Table 
1 of the introduction of this thesis). 
            This suggests that in MS and other autoimmune diseases, common pathways are involved 
in pathogenesis. When different autoimmune disorders share susceptibility genes, one would expect 
relatives to be not only at greater risk for MS than the general population, but also at greater risk of 
other autoimmune disorders. Several studies have investigated the rate of autoimmune diseases in 
MS patients and their biological relatives.106-109 The results have been conflicting, which may relate to 
differences in methodologies and populations studied.
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It is striking to note that some immunomodulatory treatments in MS can trigger other 
autoimmune diseases. The results of a phase II clinical trial with the lymphocyte-depleting humanized 
monoclonal antibody alemtuzumab (Campath-1H; targeting CD52 a protein present on the surface 
of mature lymphocytes) show that it is highly effective in the treatment of early relapsing-remitting 
MS.110 A single pulse of treatment results in rapid, profound and prolonged lymphopenia. Especially 
CD4+ T cells recover slowly, remaining depleted for at least 5 years.111 Thirty % of patients developed 
autoimmunity months to years after pulsed treatment with alemtuzumab. Most people develop thyroid 
autoimmunity, mainly Graves’ disease, and a few idiopathic thrombocytopenic purpura (ITP) and in a 
very few other blood components are targeted. In addition 5.5 % of patients develop sustained non-
thyroid autoantibodies without clinical disease.111 While the association between lymphopenia and 
autoimmunity is well recognized, most lymphopenic subjects do not develop autoimmunity. It has 
been shown that autoimmunity arose in those patients with greater T-cell apoptosis and cell cycling 
in response to treatment. This phenomenon is driven by higher levels of IL-21. Patients who went on to 
develop autoimmunity had more than 2-fold higher levels of serum IL-21 than the patients who did not. 
The production of IL-21 seems to be genetically determined.110 
These findings may suggest that by driving cycles of T cell expansion and apoptosis to excess, IL-
21 increases the stochastic opportunities for T cells to encounter self antigen and so for autoimmunity.110 
Near future
The identified risk variants only explain part of the total genetic risk of MS. With the exception of 
TYK2, the identified risk variants are all common. Larger GWAS will probably result in identifying more 
common risk variants with modest effects on disease risk. As alleles with a MAF below 0.05 are seldom 
included in GWAS because of the difficulties in detecting moderate genetic effects at this frequency 
level,7 rare variants are in general not identified with these GWAS. Whole exon sequencing or whole 
genome sequencing will be necessary to identify risk alleles with a frequency lower than 5% with effects 
in between common SNPs and very rare alleles (mutations). 
The newly identified genetic associations support the view that MS is an autoimmune disease 
in which T-cells and inflammatory responses have a dominant role. However, the GWAS described in 
chapter 5 suggests that the neurodegenerative phase is also influenced by neuronal genes. The next 
step in MS genetics will be to identify the real disease-mediating variants in the recently discovered 
genetic risk loci. One of the major tools will be DNA sequencing around the current SNPs, or even at the 
whole genome level. 
The identification of the exact disease susceptibility genes does not necessarily define the 
pathway involved in disease development or the molecular pathway the gene product is involved in. 
To determine this, functional studies are necessary. Potential effects of disease-associated variants could 
first be analysed in cells and tissues from healthy controls that may or may not have the predisposing 
genotype. Next, functional and expression analyses can be done, as the newly discovered genetic 
variants may be located in either known or putative regulatory elements, or coding regions. The 
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molecular pathways where the genetic variants are involved in should of course be analysed in-depth. 
The simultaneous quantitative analyses of gene expression will be required as more risk genes become 
known. And of course the genetic variation on a genome-wide basis in a large number of individuals will 
provide a more thorough understanding of the molecular networks that are perturbed by the disease 
associated genetic variants.112 
Obtaining immune cells for such functional studies is much easier than accessing human CNS 
cells or tissue. Recent developments in the field of induced pluripotent stem cells (iPS cells) may change 
this situation. Those cells can now be generated from fibroblasts,113-115 keratinocytes116 and blood 
progenitor cells117 and are likely to revolutionize the generation of in vitro disease models. 
However, variation in gene expression is also affected by factors as epigenetic modification, 
factors that are not readily identified by SNP or DNA sequencing studies. Epigenetic modifications are 
markers of how environmental factors may influence gene expression and may be very important 
in linking genetics to environment. The identification of epigenetic processes in demyelination118 
indicates that investigating dysregulated posttranslational modifications in MS could result in a better 
understanding of its pathogenesis.
Furthermore, the network based approach in system biology can result in better knowledge 
of pathogenesis of MS and finally to better therapies. The genomic portrait of an individual may allow a 
predictive and personalized approach to therapy. In the near future this process will probably be aided by 
powerful computers, with information technologies that will manage the available information from the 
patient’s tests, the patient’s medical history and genetic history and ever evolving scientific databases.
Interaction between identified risk genes
Between the EVI5-RPL5 locus and HLA-DR15 a modest statistical interaction was found, manifesting as 
an association in the HLA-DR15 non-carriers, but not in the HLA-DR15 carriers.40 Further studies will be 
required to further analyse these possible interactions and also possible interactions between other 
identified risk alleles.
Gene-environment interactions
A challenging element of future studies will be the characterization of the environmental factors that 
interact with genetic factors to finally cause the disease. 
As I already described in the introduction,  an interaction between vitamin D and HLA-DRB1*15 
and between EBV and HLA-DRB1*15 have been shown before. Besides EBV and vitamin D numerous 
bacterial and viral infections have been described as potential candidates, as they are often associated 
with relapses of MS. However, no single infection has consistently been associated with disease.119 It is 
unclear how so many different infections could have a role in the pathogenesis of the disease and how 
they might interact with genetic factors, unless their role is non-specific, such as in creating inflammation 
or damaging the blood-brain barrier. 
A better understanding of the function of identified risk genes and their role in pathogenesis 
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of MS may not only explain how suspected environmental factors interact with such genetic factors to 
cause disease, but could also result in the identification of additional environmental risk factors.
Pharmacogenomics
Current therapies can prevent the appearance of new lesions in the central nerve system (CNS) of MS 
patients and moderate the relapsing-remitting phase, but they have much less effect on the progression 
of the disease and long-term disability. Clinical response to MS medication varies substantially among 
individual patients. A better understanding of the etiology of MS and the pathogenesis should provide 
rational bases for developing new drugs for MS. Pharmacogenomic approaches aim at identifying 
genetic variations that affect the response to certain drugs and thus may help the physician to decide 
which patients may benefit from a certain therapy and which patients are prone to develop adverse 
side effects.120  
IFNß is the most widely used disease modifying therapy for the treatment of MS. However 
its main benefits, fewer and less severe relapses as well as delayed disease progression, are seen in 
approximately 50% of patients. Thus, effectively selecting potential responders and non-responders 
before initiating this costly therapy would be preferred by patients and clinicians.120 Recently, the first 
two GWAS were done in an attempt to identify response-predictive SNPs. In these GWAS evidence was 
found for a potential correlation between genes that code for neurotransmitter-gated channels and a 
response to IFNb therapy.121,122 However, the results of these studies need to be replicated before they 
can have clinical consequences, but it brings the concept of personalized medicine somewhat closer 
to the MS patients. 
Novel genes in animal models
Work in animal models can also result in a more comprehensive understanding of the effects of individual 
genetic variations on disease development. Through the EAE model, relevant molecular pathways in 
MS have already been dissected.123 This has led to the development of new therapies, most notably 
natalizumab (Tysabri), an α4 integrin-specific antibody that blocks T cell entry into the CNS.124
The roles of predisposing genetic variants in the pathogenesis of MS can be investigated 
further by the development of a humanized form of the EAE model in which the animals express 
transgenes derived from MS patients. Humanized mice have already been used to analyse the varying 
effects of different HLA genes in MS and their conclusions are supported by complementary genetic 
data from human populations. However, so far none of the newly identified non-MHC genetic risk 
variants has been analysed in animal models for MS, but this will become possible in the near future.125
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Summary
Multiple sclerosis (MS), the most common neurological disease affecting young adults, is a chronic 
disorder. It has at least a partial immune component. The disease is characterized by inflammation, 
demyelination, and primary or secondary axonal degeneration. Clinical features include various 
neurological dysfunctions, such as visual and sensory problems, limb weakness or gait disturbance. The 
clinical course can be relapsing-remitting from onset, characterized by relapses with full recovery, or be 
primary progressive from onset, characterized by chronic disease progression without clinical remission. 
Like most other (auto)immune disorders, MS is believed to be a complex disorder, arising from complex 
interactions of both environmental and genetic factors. Typical features for complex disorders are 
the modest heritability without a classic Mendelian mode of transmission and  heterogeneity, which 
means that a large number of genes contribute to the overall susceptibility. However, for long the 
major histocompatibility complex (MHC) has been the only genetic association with susceptibility for 
MS. A recent powerful genome-wide association study (GWAS) performed by the International Multiple 
Sclerosis Genetics Consortium (IMSGC) revealed the existence of non-MHC susceptibility loci of modest 
effect. Currently, genome-wide significant association with MS has been shown for different non-MHC 
variants by further GWAS and replication studies. Identification of genes influencing susceptibility for MS 
may result in a better understanding of its pathophysiology and may reveal pathways and targets for 
therapeutical interventions.
In chapter 1, a general introduction is given on the epidemiology and genetics of MS.
In chapter 2, the pattern of familial aggregation of MS in a recently founded genetically isolated 
population in the southwest of the Netherlands was studied as part of the research program Genetic 
Research in Isolated Populations (GRIP). Around 1750 this GRIP population was founded by about 150 
individuals. Until recently there was almost no inward and outward migration in this population. During 
the last two centuries this population underwent an exponential growth. Currently, this population 
consists of > 20,000 individuals.  The availability of extensive genealogical records for this community 
allows accurate assessment of familial aggregation in this population. For our study we ascertained 48 
MS patients from the isolate. Clinical characteristics of MS patients from the isolate did not differ from 
those of Dutch outbred MS patients. Of the 48 MS patients, 24 could be linked to a common ancestor 
in 14 generations. Using genealogical information, we found that MS patients from the isolate were 
significantly more often related to each other than a non-MS control group from the same isolate. 
Chapter 3 presents our findings regarding the parental relationship of MS patients that could 
be linked to a common ancestor. This study was performed in the same community as described in 
chapter 2. We showed that mothers of MS patients were more closely related than their fathers. This 
skewed relationship shows evidence for a maternal effect in MS.
In chapter 4 the results of two studies are reported in which we replicated the 17 risk single 
nucleotide polymorphisms (SNPs), located in 14 loci, identified in the recent GWAS from the IMSGC. 
The first study (chapter 4.1) was performed in the GRIP population. Apart from the HLA locus, 
the EVI5 gene on chromosome 1 was confirmed as a novel risk gene. The fact that despite the small 
sample size of this study, evidence for EVI5 as a risk allele for MS was found, underlines the strength of 
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studying genetically isolated populations in complex diseases. Subsequently, this finding was validated 
for the general MS population in an independent set of MS patients from the Canadian Collaborative 
Project on the Genetic Susceptibility to MS (CCGPSMS). Again, a weak but significant risk effect was 
observed, which strengthens the evidence that EVI5 is a risk gene for MS.
The second replication study (chapter 4.2) was performed in three independent cohorts: in 
MS patients from the GRIP population, in MS patients from the Dutch general population, and in MS 
patients from the CCPGSMS. Results obtained in this study were also pooled with those obtained in 
the original IMSGC study and with those obtained in a recent Australian replication study. After meta-
analysis, genome-wide significant association with MS was found for six out of the 17 SNPs in five 
different loci: HLA, CD58, CLEC16A, IL2R and IL7R. The overall ORs of the non-HLA SNPs were modest, 
between 1.16 and 1.23. We calculated the predictive power of the 14 by the IMSGC identified risk loci. 
The predictive power was too low to have clinical significance, for example for diagnostic or prognostic 
purposes. The discriminative accuracy of HLA alone was better than the discriminative value of the other 
13 genes together.
In chapter 5, we show the results of a GWAS we did in the GRIP population. We reasoned 
that the relative homogeneity of the population would be advantageous. No SNP in this GWAS showed 
genome-wide significant association with MS. However, a signal in the KIF1B locus on chromosome 1 
was detected, that was characterized by multiple associated SNPs. After a logistic regression analysis 
only one SNP (rs10492972), located in intron 5 of KIF1B remained significantly associated with MS. 
The association with the other SNPs was most likely due to linkage disequilibrium (LD) with the SNP 
rs10492972. Since KIF1B is known to encode a protein involved in axonal transport, we followed-up that 
SNP in three replication cohorts of MS patients: a cohort from the Dutch general population, a cohort 
from the Swedish general population and a cohort from the CCPGSMS. In each replication cohort, 
rs10492972 was significantly associated with MS. A meta-analysis of the results even showed a genome-
wide significant association with MS. Most earlier identified risk genes do have a function in the immune 
system and have overlapping associations with other autoimmune diseases. Our study for the first time 
identified a risk gene with specificity for the central nervous system, which may explain part of the 
progressive neurodegeneration seen in MS patients.
Finally, chapter 6 provides a discussion of our main findings and how these fit into current 
knowledge of MS genetics and pathogenesis. Furthermore, future prospectives in MS genetics and the 
consequences for the understanding of the pathogenesis of MS and the development of new therapies 
for MS are discussed. 
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Multiple Sclerose (MS), de meest voorkomende neurologische ziekte onder jong volwassenen, is een 
chronische aandoening. Het betreft meest waarschijnlijk een auto-immuun aandoening en wordt 
gekenmerkt door ontsteking, demyelinisatie en primaire of secundaire axonale degeneratie. De ziekte 
presenteert zich door neurologische uitvalsverschijnselen zoals visusverlies, gevoelsstoornissen, 
krachtsverlies of problemen met de coördinatie. Het beloop kan vanaf het begin ‘relapsing-remitting’ 
zijn en wordt dan gekenmerkt door exacerbaties van de ziekte en remissies. Ook kan het beloop direct 
progressief zijn zonder enige remissies. Zoals van de meeste (auto-)immuun aandoeningen wordt ook 
van MS gedacht dat het een complexe ziekte is, die tot uiting komt door complexe interacties tussen 
genetische en omgevingsfactoren. Bij complexe aandoeningen speelt erfelijkheid een bescheiden rol, 
zijn meerdere genen betrokken bij het tot uiting komen en ontbreekt een typische Mendeliaanse wijze 
van overerving. Tot voor kort vormde het ‘major histocompatibility complex’ (MHC) de enige genetische 
associatie met MS. In een recent door de ‘International Multiple Sclerosis Genetics Consortium’ 
(IMSGC) verrichte genoomwijde associatie studie (GWAS) werden voor het eerst ook non-MHC genen 
geïdentificeerd met een bescheiden effect op het risico op MS. Middels GWAS en replicatie studies 
is nu van meerdere non-MHC genen een genoomwijd significante associatie met MS aangetoond. 
Het identificeren van genen die de kans op MS beïnvloeden zal leiden tot een beter begrip van de 
onderliggende pathofysiologische mechanismen die een rol spelen bij het tot uiting komen van MS. Dit 
zal uiteindelijk kunnen resulteren in de ontwikkeling van betere behandelingsmogelijkheden voor MS. 
In hoofdstuk 1 wordt een algemene introductie gegeven over de epidemiologie en genetica 
van MS.
In het kader van het onderzoeksprogramma ‘Genetic Research in Isolated Populations’ 
(Genetisch onderzoek in geïsoleerde populaties; GRIP) bestudeerden we in hoofdstuk 2 de familiaire 
aggregatie van MS in een recent ontstane, genetisch geïsoleerde gemeenschap in het zuidwesten van 
Nederland. Deze geïsoleerde populatie werd rond 1750 door zo’n 150 individuen gesticht. Tot voor kort 
was er nauwelijks migratie vanuit en naar het isolaat. Gedurende de laatste 200 jaar onderging deze 
populatie een exponentiële groei. Op dit moment bestaat de populatie uit meer dan 20.000 individuen. 
De beschikbaarheid van uitvoerige genealogie maakt deze gemeenschap uitermate geschikt voor 
het betrouwbaar onderzoeken van familiaire aggregatie. Aan onze studie namen 48 MS-patiënten 
afkomstig uit het isolaat deel. Klinische karakteristieken van deze MS-patiënten verschilden niet van die 
van MS-patiënten afkomstig uit de algehele Nederlandse populatie. Van de 48 MS-patiënten konden 24 
patiënten gekoppeld worden aan één gemeenschappelijke voorouder 14 generaties terug. Met behulp 
van de genealogische gegevens toonden we aan dat MS-patiënten afkomstig uit het isolaat significant 
vaker aan elkaar verwant waren dan een willekeurige controle groep van niet-MS-patiënten afkomstig 
uit het isolaat. 
In hoofdstuk 3 onderzochten we of de moeders van MS-patiënten uit de GRIP populatie, die 
te koppelen waren aan een gemeenschappelijke voorouder, nauwer aan elkaar verwant waren dan de 
vaders. Dit bleek inderdaad het geval te zijn, wat sterk suggereert dat een maternaal effect een rol speelt 
bij het beïnvloeden van de kans op MS. 
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In hoofdstuk 4 presenteren we de resultaten van twee replicatie studies van de 17 single 
nucleotide polymorphisms (SNPs) gelokaliseerd in 14 verschillende gen regio’s, waarvan de IMSGC een 
associatie aantoonde met MS in hun recente GWAS. 
De eerste replicatie studie (hoofdstuk 4.1) werd uitgevoerd in de GRIP populatie. We 
bevestigden de reeds bekende relatie tussen HLA en MS. Tevens toonden we aan dat EVI5, gelokaliseerd 
op chromosoom 1, een risicogen is voor MS. Het feit dat een relatie kon worden aangetoond tussen 
EVI5 en MS in deze relatief kleine populatie bevestigt de kracht van het gebruik van een genetisch 
isolaat voor het bestuderen van de genetica van complexe aandoeningen. Vervolgens hebben we onze 
bevinding gevalideerd in een onafhankelijke populatie bestaande uit MS-patiënten die deelnamen aan 
het ´Canadian Collaborative Project on the Genetic Susceptibility to MS´ (CCPGSMS). Opnieuw kon een 
zwakke, maar significante associatie van EVI5 met MS worden aangetoond. 
De tweede replicatie studie (hoofdstuk 4.2) werd uitgevoerd in drie onafhankelijke cohorten: 
MS-patiënten afkomstig uit GRIP, MS-patiënten afkomstig uit de algehele Nederlandse populatie en MS-
patiënten die deelnamen aan het CCPGSMS. Uiteindelijk werd een meta-analyse verricht waarbij de 
resultaten werden samengevoegd met die van de IMSGC en met die van een Australische groep. Er 
werd genoomwijd significante associatie voor 6 van de 17 SNPs, gelokaliseerd in 5 verschillende loci 
aangetoond: HLA, CD58, CLEC16A, IL2RA en IL7R. De odds ratio’s van deze non-HLA SNPs waren laag (1,16-
1,23). We toonden aan dat de voorspellende waarde van de 14 door de IMSGC geïdentificeerde risico 
varianten laag was, en geen consequenties zal hebben voor de klinische praktijk zoals voor diagnostische 
of prognostische doeleinden. De discriminatieve waarde van enkel HLA bleek beter te zijn dan die van 
de andere 13 gen loci samen (0,63 versus 0,60). 
In hoofdstuk 5 tonen we de resultaten van een GWAS die we uitvoerden in de GRIP populatie. 
Geen enkele SNP in deze GWAS toonde een genoomwijd significante associatie met MS, maar in het 
KIF1B locus op chromosoom 1 bevonden zich wel meerdere SNPs die een associatie toonden. Na een 
logistische regressie analyse bleef slechts één SNP (rs10492972), gelokaliseerd in intron 5 van het KIF1B 
gen, significant geassocieerd met MS. Meest waarschijnlijk was de associatie met de andere SNPs het 
gevolg van ‘linkage disequilibrium’ (LD) met de SNP rs10492972. Vanwege het feit dat KIF1B ook een 
eiwit codeert wat betrokken is bij axonaal transport, hebben wij de desbetreffende SNP gerepliceerd 
in 3 cohorten MS-patiënten: een cohort afkomstig uit de algehele Nederlands populatie, een cohort 
afkomstig uit Zweden en een cohort dat deelnam aan het CCPGSMS. In elk cohort bleek rs10492972 
significant geassocieerd te zijn met MS. Een meta-analyse van de resultaten leverde zelfs een 
genoomwijd significante associatie op van rs10492972 met MS. Onze studie is de eerste waarin een 
risicogen wordt geïdentificeerd met specificiteit voor het centraal zenuwstelsel. Mogelijk kan het deels 
de neurodegeneratieve component van MS verklaren.
Tenslotte worden in hoofdstuk 6 de belangrijkste bevindingen van onze studies besproken, 
waarbij we ze in een breder perspectief plaatsen. 
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